QUARTERLY REPORT

H1 FY2020 — Results booklet

H1 FY2020PDF · 42 pages618 KB
17243_Discovery Interim Results Book • Proof 3 • 20 February 2020
and cash dividend declaration
for the six months ended
31 December 2019
RESULTS AND COMMENTARY

-- 1 of 42 --

Gross inflows under management
(R million)
2015
2016
2017
2018
2019
 
74 774
67 541
60 655
55 202
49 335
Embedded value
(R million)
2015
2016
2017
2018
2019
 
73 184
68 025
60 408
53 309
56 525
Normalised profit from operations
before investment in new initiatives
(R million)
2015
2016
2017
2018
2019
 
4 554
4 354
4 202
3 488
3 029
Core new business API
(R million)
2015
2016
2017
2018
2019
 
9 523
9 066
7 814
7 164
6 440

-- 2 of 42 --

FINANCIAL PERFORMANCE
Over the six months ended 31 December 2019, all of Discovery’s
established and emerging businesses, with the exception of
VitalityLife, produced robust operating results. VitalityLife was largely
impacted by its previously-announced strategic decision to mitigate
its exposure to further interest rate declines in the United Kingdom.
In addition, the Group continued its increased investment into new
strategic initiatives – with Discovery Bank, VitalityInvest and Vitality1
showing encouraging traction, and spend fully provided for in the
capital plan.
As a result, Discovery’s normalised profit from operations decreased
by 7% to R3 551 million, headline earnings decreased by 9% to
R2 047 million and normalised headline earnings decreased by
11% to R2 117 million. New business annualised premium income
(API) increased by 17% to R11 116 million (and by 5% to R9 523 million
excluding Vitality Group and the take-on of new closed medical
schemes in Discovery Health). The R9 523 million also excludes Vitality
Group gross revenue.
Normalised profit from operations
Current
period, in
ZAR million
Current
period
compared
to prior,
% change
Discovery Health 	R1 575 	+8%
Discovery Life 	R1 875 	+25%
Discovery Invest 	R485 	+7%
Discovery Vitality 	R5 	-75%
Discovery Insure 	R75 	+21%
VitalityHealth 	R495 	+11%
VitalityLife 	(R134) 	-145%
Vitality Group 	R110 	+16%
Ping An Health 	R68 	+467%
Operating profit before investment
in new initiatives 	R4 554 	+5%
Spend on new initiatives 	(R1 003) 	+81%
Operating profit after investment
in new initiatives 	R3 551 	-7%
In terms of the operating model, the established businesses
delivered a robust performance, with profit of R4 301 million, 3%
higher than the prior period despite the loss in VitalityLife. The
Commentary
emerging businesses grew strongly, delivering a combined profit of
R253 million, 50% higher than the prior period. In addition, the
Group invested R1 003 million in new strategic initiatives, an increase
of 81% over the prior period. Spend on new initiatives is weighted
towards the first half of the year and expected to decrease in the
second half. Of this spend, 53% was dedicated to Discovery Bank,
which is expected to remain the dominant investment going forward.
Performance of cash and capital metrics remained within guidance,
with the Group’s Financial Leverage Ratio at 24.3%1 and the cash
buffer at R2.5 billion.
Normalised headline earnings per share (diluted)2 decreased by 12%
to 322.3 cents and headline earnings per share (diluted)2 decreased
by 10% to 311.7 cents.
AMBITION 2023 AND DISCOVERY’S
UNIQUE FOUNDATION
As previously mentioned, Discovery has set a bold Ambition for 2023,
of being a leading financial services organisation globally, positively
influencing 100 million lives – with 10 million directly insured – and
being a powerful force for social good. Central to achieving this is
Discovery’s unique foundation – its core purpose, values, people and
brand, which all inform a recursive R&D agenda that continually
refines the Shared-Value model.
Over the period, there was substantial advancement of the Group’s
R&D agenda, including ongoing development of Shared-Value capability
across the Group (Vitality Money, Active Rewards 2020); industry
capability across silos (Bank, corporate productivity and Shared-Value
health insurance) and across all aspects of Discovery’s value chain
(Vitality D2C, Vitality Running World Cup).
The globalisation of Discovery’s Vitality Shared-Value model is being
enabled by Vitality1, the globally unified systems platform. Vitality1 is
live in nine markets after 18 months of operating, touching two
million members and creating efficiencies in rolling out in new
markets. Every day the platform logs more than four million
workouts and allocates more than 35 000 rewards.
As mentioned previously, achieving the Ambition will require continued
execution of market-specific strategies:
South Africa: a disruptive composite model, with market-leading
businesses and a successful entry into banking
United Kingdom: a differentiated offering through a composite
Vitality Shared-Value model
Ping An Health: the leading health insurer in China with over
50 million clients
Vitality Group: a sophisticated global behaviour-change platform
linked to financial services
Robust performance in a complex period with substantial investment in new initiatives
and core businesses performing well with the exception of VitalityLife
1 Excludes capitalised lease liabilities under the newly adopted IFRS16 and bank borrowings related to normal course lending and borrowing activities.
2 The percentage change in the current period is the same for both undiluted and diluted earnings per share.
1

-- 3 of 42 --

SOUTH AFRICA
Discovery Bank
During the period, focus was on leveraging key strategic
advantages to build a retail heavy bank of scale; demonstrating
the efficacy of the Vitality Shared-Value model in banking and
creating an appealing customer proposition; using Discovery’s
unique data capability; and executing on a lower cost-to-income
FinTech infrastructure – ultimately ensuring the Bank is a composite
maker for the Group.
As at 18 February 2020, Discovery Bank had 78 000 clients with
180 000 accounts, nearly half of which had never held a Discovery
Card before; deposits had grown strongly to R1.2 billion; total
credit card spend was R2.6 billion and total credit limits granted
was R2.5 billion – with over R1 billion in credit facility used. Early
member engagement is positive and the client base is exhibiting
appealing spend, credit, arrears and deposit behaviour, better
than the performance of the previous Discovery Card and
considerably better than the market. Growth potential is strong
with over 200 000 accounts that still need to be migrated from
the FNB Joint Venture; and the activation of Discovery’s advisor
channels to sell bank accounts in the second half of the year.
Early indications are encouraging that the Vitality Shared-Value model
is working in banking – where interest rates and incentives are tiered
by financial behaviour and wellness as measured through Vitality
Money. Strong correlations are being observed by Vitality Money
status in credit utilisation, deposits, spending and defaults – across
the client base and account types. Engagement and correlations are
even stronger for clients with multiple Vitality products.
The Discovery Bank build, testing and running have been achieved
within budget while delivering a number of innovations such as
mobile onboarding in less than five minutes, Health Banking and
Discovery Miles. Priorities include simplifying the Vitality Money user
experience and streamlining the service environment and online
support functionality.
Discovery Health
The strategic focus over the period was on sustaining growth
in a contracting medical scheme market; managing medical
inflation while optimising cost and quality; reducing administration
costs while maximising service; and ensuring the increasing
financial strength and competitive position of Discovery Health
Medical Scheme (DHMS).
Discovery Health (DH) delivered a resilient performance, with
normalised operating profit increasing by 8% to R1 575 million.
Total new business API (including take-on of new closed medical
schemes) grew by 26% to R4 367 million.
New business API (excluding Vitality and the take-on of new
closed medical schemes) was affected by the challenging economic
environment and slower employment growth, declining 4%
relative to the prior period, though still robust at R3 289 million.
Traditional new membership from employees joining DHMS
employer group clients, which has historically characterised
DHMS growth, has retracted and is being replaced by individual
members joining DHMS in their personal capacity; the ratio of
these sources of growth has thus inverted. DHMS delivered a
strong performance, with a projected positive operating result
before investment income, and solvency of 27.3% for the scheme
year ending 31 December 20193
. The average contributions of
DHMS are 16.7% lower than those of competitors per unit of
healthcare benefit.
The continued efficacy of the Shared-Value model was evident over
the period, with engaged Vitality members’ hospital costs 28%4
lower and their lapse rate more than 3.6 times lower than non-
Vitality members. Furthermore, the business continued to invest in
building out its value-based care initiatives, with 39% of hospital
payments now under risk share contracts. DH’s disease management
programmes continued to demonstrate value, with total cost of care
for a member on the Diabetes Care programme being materially
lower than for a non-registered diabetic member.
The business continued to deliver on its objective of growing non-
scheme revenue through expanded product offerings, including
Discovery Primary Care, Gap Cover and Healthy Company. These
products are gaining traction, with a total membership of
approximately 138 000 as at 31 December 2019. This has driven non-
scheme earnings growth to 84% higher than the prior year.
DH continued to invest in digital technologies and automation to
extract operational efficiencies, drive down healthcare costs and
improve member experience – with over R400 million spent on
technology over the period. Multiple projects are underway including
robotic process automation, natural language processing speech-to-
text conversion, optical character recognition document interpretation,
AI virtual assistant technology and instant messaging chat-service
channels. These investments support ongoing operational efficiency
improvements, with DH operational expenses decreasing by 6% on a
per member basis from 2016 to 2019 in real terms, and call rates
decreasing by 19% from 2015 to 2019.
DH is supportive of a National Health Insurance (NHI) system that
improves the healthcare system for all South Africans. The publication
of the NHI Bill creates an important opportunity for active collaboration
between the Department of Health and the private healthcare sector,
and Discovery Health continues to engage with relevant stakeholders
to participate in the creation of a sustainable public and private
healthcare system. The Bill is not expected to have a material long-
term impact on DH and may in fact present new opportunities for
growth and product innovation. DH remains of the view that there is
an ongoing critical role for medical schemes and private healthcare
providers going forward.
Discovery Life
The strategic focus over the period was on optimising growth
and quality of new business; achieving positive operational
experience variances; ensuring balance and correct correlations
within the Shared-Value model; and ensuring products have
relevance through member value and engagement.
Discovery Life (DL) had an excellent period, growing earnings by
25% to R1 875 million (off a low base) as a result of improving
claims experience and pleasing all-round performance. New
business grew 2% to R1 240 million in a declining market,
resulting in over 31% market share in the retail affluent risk
market – more than double the next largest competitor. DL
performed strongly against EV assumptions with improvement
across all non-economic experience such as claims, lapses,
policy alterations and Vitality status experience, leading to a
positive overall EV variance in Life and Invest. The business
remains well capitalised with an above-target SCR coverage of
172%, and generated cash in line with plan.
The Shared-Value model continued to deliver results, with highly
engaged Vitality members experiencing less than 50% mortality
and more than 15% fewer lapses than non-Vitality members. More
than R1 billion in PayBack was paid in calendar year 2019 due to high
Vitality engagement.
3 Note that the DHMS results remain subject to finalisation through the annual independent audit currently underway.
4 Based on 2018 data.
2	Unaudited interim results and cash dividend declaration December 2019

-- 4 of 42 --

5 Per Morningstar at 31 December 2019.
Looking forward, DL is focused on driving new business growth and
market share without compromising the VNB margin, and launching
a comprehensive suite of products in March 2020 to target the
individual risk market and tap into adjacencies. The general economic
environment remains challenging, and despite the operational
elements of the business being repositioned, interest rates remain a
medium-term concern especially with sovereign credit ratings risk.
Discovery Invest
The strategic focus over the period was on growing new
business and assets under management in a market attracting
low inflows; evolving a unique long-term Shared-Value model in
a market experiencing commoditisation and market pressure;
and ensuring superior overall financial outcomes for customers.
Discovery Invest’s performance was robust in an environment
of weakened inflows. Operating profit grew by 7% to R485 million
and assets under administration by 16% to R96.7 billion, driven
by improved market performance at the end of the period. Over
78% of linked funds were placed in Discovery funds. Net inflows
were strong relative to the industry at R2.3 billion. Sales were
affected by the weak inflow environment, seeing new business
(including ACIs) declining by 2% to R1 357 million. The Discovery
Balanced Fund continued to perform well and was in the first
performance quartile in its sector for three, five, and ten years5
.
At the end of the third quarter, Discovery Collective Investments
was the sixth highest retail flow taker, excluding money market
funds, with a substantial proportion of flows going to high-
margin business.
Discovery Invest continued to successfully apply the Shared-Value
model in the long-term savings market, with engaged Vitality clients
exhibiting 12.7% lower drawdowns, up to 13.5% reduced withdrawals
and three times more ad-hoc contributions to their savings.
Over the period, considerable work was done to understand the
science behind the Shared-Value model in retirement savings with a
focus on behavioural factors. These learnings position Discovery
Invest strongly for the future given the importance of behaviour in a
defined-contributions environment, and the platform’s ability to
bring together administrative and behavioural attributes. This has
already manifested in the recently launched Purple range of lump-
sum retirement products, which provide reduced boosts on external
funds for the first time. Innovating in the long-term savings market
remains a strategic priority, with several initiatives in the pipeline for
the March 2020 launch.
Discovery Insure
The strategic focus over the period was on quality growth in the
mass affluent space and ensuring the integrity of the Shared-
Value model so that with duration – profit, scale and materiality
emerge.
Discovery Insure (DI) saw strong growth during the period,
achieving R75 million operating profit – up 21% on the prior year.
Gross Premium Income grew by 15% to R1.8 billion while gross
new business API grew by 7% to R551 million. Gross Written
Premium (personal lines only) market share was estimated at 6%.
DI has attracted a disproportionate share of the higher-valued
vehicles in the market, which in turn has translated to higher-than-
average premiums compared to the market. The period saw continued
evidence of the efficacy of the Shared-Value model in Discovery
Insure: increased efficiencies, realised by lower staff headcount per
policy; up to 44% of claims captured digitally and automatically
processed using artificial intelligence; and continued selective
lapsation working as per the model, is manifesting in a steadily
declining expense ratio. The proportion of good drivers – who displayed
an up to 34% lower loss ratio and 67% lower lapse rate compared with
bad drivers – is increasing by duration of years inforce. This coupled
with improving loss ratios by status and policy durations implies a
declining future loss ratio.
The actuarial dynamics of the Shared-Value model in commercial
insurance are excellent and extend to both fleets and non-motor lines,
with the rewards components adapted to suit the market. In terms of
strategic focus areas going forward, the commercial lines business
continued to grow and receive good adviser support. A key priority is
developing a specialist tied advisory force dedicated to writing
commercial business. The first 19 advisors began in February 2020
and will grow to 40 advisers by June 2020.
Following the success of Avis SafeDrive in South Africa, DI launched
the programme in the Netherlands. This represents part of DI’s
strategic objective to explore opportunities to extend its model into
international markets.
UNITED KINGDOM
The strategic focus over the period was on pursuing the composite
strategy. For the six months, combined new business increased
by 12% to £76.4 million (R1 416 million, up 14%) and total lives
exceeded 1.29 million, an increase of 12%. Normalised operating
profit for VitalityHealth (VH) and VitalityLife (VL) reduced by
52% to £19.5 million (R361 million) – after the impact of interest
rates and the interest rate hedge for VL. The hedged position
provides a greater degree of certainty and enables operating
within risk tolerance levels.
Using Vitality as a mechanism to amplify Shared Value across the UK
businesses remains a key strategic focus. In pursuit of this strategy,
a composite product offering providing enhanced benefits to
members who hold multiple Vitality products was launched in
November 2019. This included work with American Express to launch
a Vitality card and a partnership with UK food retailer Waitrose &
Partners as key mechanisms for delivering composite rewards. The
strategy is supported by a new composite online member journey
(launched December 2019), and a member app (planned for release
in March 2020).
The structure of the business is being adapted to deliver this
composite strategy, by combining several functions that span VH and
VL in key areas such as servicing, retentions, sales support and
information technology. The aim is to provide an integrated, intuitive
service to customers and advisers, while generating efficiencies.
VitalityHealth
The strategic focus over the period was on maintaining
exceptional quality of new business; delivering personalised
healthcare pathways through digital; and ensuring service
quality.
VitalityHealth continued to deliver strong results. Operating
profit grew by 9% to £26.7 million (up 11% to R495 million),
although new business declined by 2% to £33.1 million (0.5% to
R613 million) in a challenging sales environment, characterised
by economic uncertainty and aggressive competitor activity.
Total lives reached 674 000, up 12%, while earned premiums
grew 9% to £246.5 million (R4 569 million). The results reflect
continued strong performance across key business metrics: the
lapse rate and claims performance was stable and costs remained
well managed.
3

-- 5 of 42 --

Embedded Value grew by 5% over the period, with positive
experience variances driven by retention efforts. The back book was
strongly cash flow positive, generating £50.8 million (R942 million) in
cash. After new business acquisition costs and investment in
developing the business, VH generated a £14.8 million (R274 million)
cash surplus.
The business sustained its significant investment in leading servicing
and digital technologies, with a focus on customer service. This
resulted in it being awarded first place in the Top 50 Companies for
Customer Service Awards (the UK’s largest customer service
benchmarking programme covering over 300 companies across a
range of sectors) in January. Data science is at the core of VH’s
strategy, and the business continued to apply sophisticated machine
learning in multiple contexts over the period. The results are
compelling and learnings will be applied to VitalityLife.
VitalityLife
The strategic focus over the period was on stabilising the impact
of external factors on the business; addressing non-economic
variances through quality of new business and retention; and
right-sizing the business for the environment.
VL new business API grew by 6% to £34.8 million (8% to R646 million),
and earned premiums by 12% to £141.4 million (R2 620 million).
Lives covered and in-force policies both grew strongly by 12%,
exceeding 605 000 and 458 000 respectively. Operating profit
declined to -£7.2 million (-R134 million). This includes a negative
impact of £16 million due to the hedge structure and related
impacts, as well as negative lapse experience, resulting in
embedded value reducing by 1%.
In response to the environment, VL implemented the interest rate
hedge, adapted the legal structure of the business, optimised its
capital position, and has deferred the Part VII transfer of the VL back
book written on the Prudential Assurance Company’s licence by
three years. The impact of low interest rates is expected to remain a
feature of the profits for the remainder of the year.
This and other initiatives are being put in place to right-size the
business for this environment and the benefits of these changes are
expected to materialise over the next financial year. A reduction in
expense run rate is marked to manifest once various measures have
been effected, such as reorganising the franchise distribution
channel and combining key service elements across the Group. The
negative experience variances have been analysed and management
actions are in place. Adviser firms with significantly higher-than-
expected lapse rates have been identified, and commission clawback
terms for these firms have been extended, with the experience being
monitored continually.
VitalityInvest
The strategic focus over the period was on new business growth
and product development to support this. VitalityInvest (VI) has
made substantial progress, with new business annual premium
equivalent (APE) of £8.5 million6 (R157 million) over the period,
equating to month-on-month growth of 17% and total funds
under management of £105.3 million (R1 952 million).
The January launch saw a significant repositioning of product,
underpinned by the Vitality Shared-Value Invest platform – a combination
of Vitality, which is now embedded in all plans, and VI’s market-leading
transactional capabilities. The platform leverages Shared Value to
address the behavioural challenges related to longevity and poor
health. In addition, VI launched a fund range in partnership with SEI,
one of the world’s largest manager-of-managers, as well as a range of
blended funds that bring together index-tracking and actively
managed solutions. The above momentum, together with product
development and enhanced distribution, should see the business
make significant progress towards its full-year target.
PING AN HEALTH (PAH)
The strategic focus over the period was on delivering on PAH’s
ambition of being the leading health insurer in China; driving
quality of new business; and continuing to invest for growth and
scale.
PAH had a remarkable period, with total revenue growing by
56% to RMB5.3 billion (R11.1 billion), and new business premium
growing over 27% to RMB2.6 billion (R5.5 billion). PAH exceeded
its written premium target of RMB10 billion for the 2019 calendar
year. The Group’s share of after-tax operating profit grew by
467% to $4.6 million (R68 million). The tax relief on deductible
commissions effected in May 2019 resulted in the effective tax
rate reducing to 41% for the period (December 2018: 55%).
PAH continued to invest considerably in technology skills, with
technology related labour-costs growing substantially in response to
PAH’s internet strategy. It also strengthened the team to maintain
branch expansion. The investment in scaling online operations to
support its vision of becoming China’s leading tech-driven health
insurer is beginning to manifest. Significant enhancements were made
to the PAH app, to more effectively enable a full mobile user experience
and strong direct-to-consumer sales channel. The app achieved
growth of 138% over the past year, and as at 31 December 2019 had
19.4 million registered users, with a growth rate of approximately one
million new users each month. The proportion of online to overall
business continued to increase, accounting for 11.6% of overall business
(RMB1.22 billion) – growth of 243% year-on-year.
A key strategy for the app is HelloRun Club, PAH’s digital-only version
of Vitality, which is used to attract new users to the app, drive
engagement among existing customers and increase sales. At the
end of 2019, HelloRun Club had over five million members. Ping An
Run Vitality celebrated its three-year anniversary in the period, and
has over six million members.
PAH introduced an industry-leading smart claims system, E Flash
Claims. This system has optimised the quality and efficiency of
operational services to further improve customer experience, and
reduced the average claims turnaround time from 1.5 days to 10
minutes. In addition, in 2019 PAH won several awards including Best
Health Insurance Brand of the Year, Socially Responsible Insurer of
the Year and Product Innovation Excellence Award.
In terms of the COVID-19 virus, it is expected to have limited business
impact, given that PAH is not active in Hubei; and the State Council
of China has announced that medical expenses related to the virus
will be paid for by the Social Health Insurance system. In response to
the COVID-19 virus, PAH has proactively modified and developed
products to cover specific benefits. PAH is also working closely with
the appropriate authorities in China to support clients and other
affected citizens, playing a nation-building role. This includes using
the app as a trusted source of information, offering services,
guidelines and live reports on virus-related developments.
6. APE calculated as single/10 + annual recurring.
4	Unaudited interim results and cash dividend declaration December 2019

-- 6 of 42 --

VITALITY GROUP
The strategic focus over the period was on pursuing global scale,
relevance and materiality; ensuring leading IP, technology and
data insights to deliver the best behaviour-change platform and
drive unique customer propositions; and having a transformational
impact on the business of partners.
Vitality Group (VG) delivered a pleasing set of results for the
period, achieving a profit of $7.5 million (R110 million, up 16%
from the prior year). Fee income grew to $35 million (R515 million,
up 17%), supported by strong growth in insurance partners’
integrated premiums, which reached $591.5 million (R8.7 billion).
Total Vitality membership grew to 4.5 million, of which two
million are administered on Vitality1. Membership7 from insurance
partners’ integrated products grew to 1.8 million, an increase of
63% on the prior year.
The business is in a significant period of growth, particularly with the
establishment of Vitality Health International whereby Vitality Group
will intensify its focus on global health insurance initiatives through
either equity partnerships or consulting and IP solutions. The Group
believes the opportunities are significant, given the rapid growth of
health insurance in markets around the world and Discovery’s
unique health insurance expertise, assets, and Shared-Value model;
together with its involvement in the eminent health insurance
businesses in South Africa, China and the UK.
NATIONAL CHAMPIONS
AIA Vitality
AIA Vitality continued to generate strong membership and new
business value growth over the period. The actuarial dynamics
emerging from the AIA markets are compelling – the level of
engagement is high and there is already evidence of behaviour change
and improvements in members’ health and lapse experience
consistent with that of Discovery. AIA Vitality now operates in 11
markets across Asia and Australasia, following its successful launch in
New Zealand during the period. The Harvard Business Review
recognised AIA as one of the top 20 global business transformations
over the last decade for its transformation from a traditional insurance
provider to a collaborator with consumers through AIA Vitality.
John Hancock and Manulife Vitality
Despite low growth in the US life insurance market overall, John
Hancock continued to deliver excellent results, posting an 87%
increase in sales of John Hancock Vitality for 2019; with membership
growing at a steady pace. Engagement continues to be significant for
both new and existing clients. In addition, through a partnership with
Onduo, John Hancock launched the first-ever US life insurance
product for people living with diabetes. The Vitality-enabled diabetes
management programme won a gold award for “Most Innovative
Product Feature of the Year” in the 2019 Best in Biz Awards.
Manulife took Vitality Group Benefits live to the public after a
successful internal launch, making more than 1.5 million employees
eligible for the programme.
Sumitomo Life Vitality
Sumitomo Life Vitality moved into its second year and continued to
see good growth in integrated insurance policies, penetration rates
and the creation of adjacencies. Membership growth has been rapid,
reaching significant scale in 15 months; engagement is high for both
new and existing clients; and there is clear behaviour change and
health impact. During the programme refresh in September 2019,
new partnerships with local and global rewards partners were
announced and will launch later this year.
Generali Vitality
The past six months have been dominated by the implementation
plan for the migration of Germany, France and Austria onto the new
Vitality1 platform. Encouragingly, there was a 17.6% increase in
membership over the past six months across Germany, France and
Austria in aggregate. An agreement was reached to roll out Vitality
into two new markets, and Generali continues to explore
opportunities to roll out into more markets across Europe.
FRANCHISE MARKETS
VG’s partnership with Hannover Re to expand Shared-Value
Insurance products into next-tier markets has resulted in agreements
with insurers in eight countries. Vitality Group’s first partnership in
Latin America has produced excellent results with Ecuador being
ahead of the business plan. Similarly, the Netherlands is showing
early indications of success with higher-than-projected sales
numbers. Four launches are planned for 2020.
VITALITY USA
Vitality USA delivered strong financial results, achieving a 36% increase
in profits from the prior year and a 47% increase in membership. The
membership growth was supported by the launch of the “Apple Watch
Engage” offering, a version of Active Rewards in partnership with
Apple and several consumer-facing brands. Building on the positive
response to the Aetna Attain programme, the business expanded to
high touch gym chains Orangetheory Fitness and Crunch Fitness in a
limited number of gyms as a precursor to a national roll-out.
Vitality USA has laid the groundwork for strong growth in the
employer market including the development of several strategic
partnerships; expansion of the product offering to better meet
employer needs; and optimising the distribution structure.
PRIORITIES FOR GROWTH
The Group is well positioned for growth over its planning horizon to
2023, with the capital plan intact. Key priority areas are:
1. 	Execute on VitalityLife’s stated plans to manage in the low
interest rate environment, stabilise experience variances and
return to robust profit in FY 2021
2. 	Achieve significant traction in new initiatives, most notably
Discovery Bank, and ensure short-term new business thresholds
are achieved for each initiative
3. 	Ensure the established businesses retain their insurgency
4. 	Capitalise on emerging businesses’ unique attributes and
positioning to achieve scale and materiality
On behalf of the Board
ME Tucker 	A Gore
Chairperson 	Chief Executive Officer
Sandton
19 February 2020
Notes to analysts
Any forecast financial information contained in this announcement
has not been reviewed or reported on by the company’s external
auditors.
Discovery has published supplemental unaudited information
on the website. For this and other results information, go to
https://www.discovery.co.za/corporate/investor-relations and
page down to Financial results_on reports, Interim results 2020.
7. Full Vitality membership
5

-- 7 of 42 --

R million
Group
December
2019
Unaudited
Group
June
2019
Audited
ASSETS
Goodwill 	4 705 	4 642
Intangible assets 	6 013 	5 597
Property and equipment 	4 727 	4 212
Assets arising from insurance contracts 	51 508 	48 781
Deferred acquisition costs 	518 	536
Assets arising from contracts with customers 	809 	752
Investment in equity-accounted investments 	2 229 	1 950
Deferred income tax 	2 459 	2 372
Financial assets
– Loans and advances to customers at amortised cost 	734 	–
– Investments at amortised cost 	2 191 	1 943
– Investments at fair value through profit or loss 	96 702 	90 205
– Derivative financial instruments at fair value through profit or loss 	133 	375
Insurance receivables, contract receivables and other non-financial receivables 	10 596 	9 015
Current income tax asset 	294 	136
Reinsurance contracts 	319 	314
Cash and cash equivalents 	10 329 	9 403
Total assets 	194 266 	180 233
EQUITY
Capital and reserves
Ordinary share capital and share premium 	10 148 	10 142
Perpetual preference share capital 	779 	779
Other reserves 	762 	452
Retained earnings 	32 986 	31 710
44 675 	43 083
Non-controlling interest 	6 	*
Total equity 	44 681 	43 083
LIABILITIES
Liabilities arising from insurance contracts 	74 928 	70 522
Liabilities arising from reinsurance contracts 	11 757 	10 835
Deferred income tax liability 	9 033 	8 697
Contract liabilities to customers 	318 	433
Financial liabilities
– Borrowings at amortised cost 	17 174 	14 682
– Other payables at amortised cost 	10 826 	10 262
– Deposits from customers 	992 	–
– Investment contracts at fair value through profit or loss 	22 749 	20 674
– Derivative financial instruments at fair value through profit or loss 	1 032 	509
Employee benefits 	267 	260
Current income tax liability 	509 	276
Total liabilities 	149 585 	137 150
Total equity and liabilities 	194 266 	180 233
* Amount is less than R500 000.
The order in which individual line items are presented in the Statement of Financial Position has been amended to better reflect their respective
liquidity, as far as possible, from least liquid to the most liquid items. No values were reclassified or restated between line items.
STATEMENT OF FINANCIAL POSITION
at 31 December 2019
6	Unaudited interim results and cash dividend declaration December 2019

-- 8 of 42 --

R million
Group
Six months
ended
December
2019
Unaudited
Group
Six months
ended
December
2018
Unaudited
Restated 1
%
change
Group
Year
ended
June
2019
Audited
Insurance premium revenue 	23 378 	21 301 	43 036
Reinsurance premiums 	(3 001) 	(2 741) 	(5 595)
Net insurance premium revenue 	20 377 	18 560 	10 	37 441
Fee income from administration businesses 	5 564 	4 873 	10 404
Vitality income 	2 007 	1 946 	3 653
Other income 	617 	602 	1 063
Banking interest and similar income 	48 	– 	29
Investment income 	215 	234 	398
Net fair value gains/(losses) on financial assets at fair value through
profit or loss 	2 658 	(1 766) 	4 265
Net income 	31 486 	24 449 	29 	57 253
Net claims and policyholders’ benefits 	(11 955) 	(10 177) 	17 	(20 879)
Claims and policyholders’ benefits 	(13 937) 	(12 011) 	(24 538)
Insurance claims recovered from reinsurers 	1 982 	1 834 	3 659
Acquisition costs 	(3 134) 	(2 953) 	(6 100)
Marketing and administration expenses 	(11 022) 	(9 685) 	(19 954)
Amortisation of intangibles from business combinations 	(36) 	(61) 	(99)
Credit impairment charges 	(36) 	– 	–
Banking interest and similar expenses 	(26) 	– 	–
Recovery of expenses from reinsurers 	1 512 	1 393 	2 830
Net transfer to/from assets and liabilities under insurance contracts 	(2 641) 	168 	(4 706)
– change in assets arising from insurance contracts 	2 584 	2 530 	5 321
– change in assets arising from reinsurance contracts 	(480) 	(10) 	7
– change in liabilities arising from insurance contracts 	(4 182) 	(1 595) 	(8 050)
– change in liabilities arising from reinsurance contracts 	(563) 	(757) 	(1 984)
Fair value adjustment to liabilities under investment contracts 	(584) 	703 	(809)
Profit from operations 	3 564 	3 837 	(7) 	7 536
Finance costs 	(755) 	(681) 	(1 375)
Foreign exchange gains 	44 	6 	*
Gains from dilution of equity accounted investments 	– 	51 	844
Gain on previously held interest in DiscoveryCard business 	– 	– 	761
Impairment of goodwill 	(9) 	– 	(17)
Share of net profits from equity-accounted investments 	125 	60 	170
Profit before tax 	2 969 	3 273 	(9) 	7 919
Income tax expense 	(891) 	(947) 	(6) 	(1 305)
Profit for the period 	2 078 	2 326 	(11) 	6 614
Profit attributable to:
– ordinary shareholders 	2 037 	2 286 	(11) 	6 533
– preference shareholders 	41 	40 	81
– non-controlling interest 	* 	* 	*
2 078 	2 326 	(11) 	6 614
Earnings per share for profit attributable to ordinary
shareholders of the company during the period (cents):
– undiluted 	310.3 	352.7 	(12) 	1 001.5
– diluted 	310.2 	352.5 	(12) 	1 001.1
* Amount is less than R500 000.
1 The restatements are as a result of reclassifications. The reclassifications had no effect on the reported 'Net income', 'Profit for the period' or associated earnings per share values.
The restatements do not affect any financial information published in the Annual Financial Statements for the year ended 30 June 2019. Refer to note 'Restatement due to incorrect
prior period classification'.
INCOME STATEMENT
for the six months ended 31 December 2019
7

-- 9 of 42 --

R million
Group
Six months
ended
December
2019
Unaudited
Group
Six months
ended
December
2018
Unaudited
%
change
Group
Year
ended
June
2019
Audited
Profit for the period 	2 078 	2 326 	(11) 	6 614
Items that are or may be reclassified subsequently
to profit or loss:
Currency translation differences 	354 	167 	(140)
– unrealised gains/(losses) 	354 	171 	(142)
– tax on unrealised gains/losses 	– 	(4) 	2
Cash flow hedges 	(102) 	(26) 	(175)
– unrealised (losses)/gains 	(329) 	105 	(91)
– tax on unrealised losses/gains 	50 	(26) 	(7)
– losses/(gains) recycled to profit or loss 	211 	(130) 	(98)
– tax on recycled losses/gains 	(34) 	25 	21
Share of other comprehensive income from equity-accounted
investments 	6 	3 	(19)
– change in fair value of debt instruments at fair value through other
comprehensive income 	29 	– 	–
– currency translation differences 	(23) 	3 	(19)
Other comprehensive income/(losses) for the period, net of tax 	258 	144 	79 	(334)
Total comprehensive income for the period 	2 336 	2 470 	(5) 	6 280
Attributable to:
– ordinary shareholders 	2 295 	2 430 	(6) 	6 199
– preference shareholders 	41 	40 	81
– non-controlling interest 	* 	* 	*
Total comprehensive income for the period 	2 336 	2 470 	(5) 	6 280
* Amount is less than R500 000.
STATEMENT OF OTHER COMPREHENSIVE INCOME
for the six months ended 31 December 2019
8	Unaudited interim results and cash dividend declaration December 2019

-- 10 of 42 --

R million
Group
Six months
ended
December
2019
Unaudited
Group
Six months
ended
December
2018
Unaudited
%
change
Group
Year
ended
June
2019
Audited
Basic earnings per share (cents):
– undiluted 	310.3 	352.7 	(12) 	1001. 5
– diluted 	310.2 	352.5 	(12) 	1001. 1
Headline earnings per share (cents):
– undiluted 	311.7 	347.4 	(10) 	789.0
– diluted 	311.7 	347.2 	(10) 	788.7
Normalised headline earnings per share (cents):
– undiluted 	322.4 	366.6 	(12) 	771.9
– diluted 	322.3 	366.4 	(12) 	771.6
The reconciliation between earnings and headline earnings
is shown below:
Net profit attributable to ordinary shareholders 	2 037 	2 286 	(11) 	6 533
Adjusted for:
– gain on dilution and disposal of equity-accounted investments,
net of tax 	– 	(51) 	(666)
– gain on previously held interests in DiscoveryCard business 	– 	– 	(761)
– gain on disposal of property and equipment, net of tax 	– 	– 	1
– impairment of intangible assets, net of tax 	1 	17 	23
– impairment of goodwill 	9 	– 	17
Headline earnings 	2 047 	2 252 	(9) 	5 147
– amortisation of intangibles from business combinations,
net of tax 	28 	54 	84
– cost relating to disposal of equity-accounted investments, net of tax 	– 	– 	15
– debt restructuring costs resulting from DiscoveryCard business
transaction 	– 	33 	33
– deferred tax asset raised on assessed losses 	– 	– 	(326)
– deferred tax related to Discovery Life 'new adjusted IFRS basis'
and Corporate Policyholder Fund assessed loss 	– 	– 	(38)
– initial expenses related to Prudential Book transfer, net of tax 	15 	11 	23
– transaction costs related to VitalityLife interest rate derivatives,
net of tax 	19 	– 	–
– unrealised losses on foreign exchange contracts not designated
as a hedge, net of tax 	8 	26 	97
Normalised headline earnings 	2 117 	2 376 	(11) 	5 035
Weighted number of shares in issue (000's) 	656 623 	648 030 	652 295
Diluted weighted number of shares (000's) 	656 805 	648 318 	652 568
HEADLINE EARNINGS
for the six months ended 31 December 2019
9

-- 11 of 42 --

Attributable to equity holders of the Company
R million
Share capital
and share
premium
Preference
share
capital
Share-based
payment
reserve
Period ended 31 December 2019
At beginning of the period 	10 142 	779 	41
IFRS transitional adjustments 	– 	– 	–
Adjusted balance at beginning of the period 	10 142 	779 	41
Total comprehensive income for the period 	– 	41 	–
Profit for the period 	– 	41 	–
Other comprehensive income 	– 	– 	–
Transactions with owners 	6 	(41) 	52
Delivery of treasury shares 	6 	– 	(6)
Acquisition of subsidiaries with non-controlling interest 	– 	– 	–
Employee share option schemes:
– Value of employee services 	– 	– 	58
Dividends paid to preference shareholders 	– 	(41) 	–
Dividends paid to ordinary shareholders 	– 	– 	–
At end of the period 	10 148 	779 	93
Period ended 31 December 2018
At beginning of the period 	8 308 	779 	327
IFRS transitional adjustments 	– 	– 	–
Adjusted balance at beginning of the period 	8 308 	779 	327
Total comprehensive income for the period 	– 	40 	–
Profit for the period 	– 	40 	–
Other comprehensive income 	– 	– 	–
Transactions with owners 	1 840 	(40) 	7
Delivery of treasury shares 	3 	– 	–
Share issue 	1 854 	– 	–
Share issue costs 	(17) 	– 	–
Change in ownership without change in control 	– 	– 	–
Employee share option schemes:
– Value of employee services 	– 	– 	7
Dividends paid to preference shareholders 	– 	(40) 	–
Dividends paid to ordinary shareholders 	– 	– 	–
At end of the period 	10 148 	779 	334
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at
FVOCI, in terms of IFRS 9 Financial Instruments.
* Amount is less than R500 000.
STATEMENT OF CHANGES IN EQUITY
at 31 December 2019
10	Unaudited interim results and cash dividend declaration December 2019

-- 12 of 42 --

Attributable to equity holders of the Company
Investment
reserve 1
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-controlling
interest 	Total
– 	585 	(174) 	31 710 	43 083 	* 	43 083
– 	– 	– 	(13) 	(13) 	– 	(13)
– 	585 	(174) 	31 697 	43 070 	* 	43 070
29 	331 	(102) 	2 037 	2 336 	– 	2 336
– 	– 	– 	2 037 	2 078 	– 	2 078
29 	331 	(102) 	– 	258 	– 	258
– 	– 	– 	(748) 	(731) 	6 	(725)
– 	– 	– 	– 	– 	– 	–
– 	– 	– 	– 	– 	6 	6
– 	– 	– 	– 	58 	– 	58
– 	– 	– 	– 	(41) 	– 	(41)
– 	– 	– 	(748) 	(748) 	– 	(748)
29 	916 	(276) 	32 986 	44 675 	6 	44 681
208 	744 	1 	27 227 	37 594 	* 	37 594
(208) 	– 	– 	131 	(77) 	– 	(77)
– 	744 	1 	27 358 	37 517 	* 	37 517
– 	170 	(26) 	2 286 	2 470 	– 	2 470
– 	– 	– 	2 286 	2 326 	– 	2 326
– 	170 	(26) 	– 	144 	– 	144
– 	– 	– 	(1 840) 	(33) 	– 	(33)
– 	– 	– 	– 	3 	– 	3
– 	– 	– 	– 	1 854 	– 	1 854
– 	– 	– 	– 	(17) 	– 	(17)
– 	– 	– 	(1 104) 	(1 104) 	– 	(1 104)
– 	– 	– 	– 	7 	– 	7
– 	– 	– 	– 	(40) 	– 	(40)
– 	– 	– 	(736) 	(736) 	– 	(736)
– 	914 	(25) 	27 804 	39 954 	* 	39 954
11

-- 13 of 42 --

R million
Group
Six months
ended
December
2019
Unaudited
Group
Six months
ended
December
2018
Unaudited
Group
Year
ended
June
2019
Audited
Cash flow from operating activities 	73 	(1 829) 	1 738
Cash generated by operations 	6 787 	5 004 	12 154
Purchase of investments held to back policyholder liabilities 	(13 227) 	(10 908) 	(35 109)
Proceeds from disposal of investments held to back policyholder liabilities 	6 639 	4 954 	23 831
Working capital changes 	(346) 	(1 026) 	625
(147) 	(1 976) 	1 501
Dividends received 	182 	149 	339
Interest received 	1 217 	1 111 	2 274
Interest paid 	(640) 	(616) 	(1 219)
Taxation paid 	(539) 	(497) 	(1 157)
Cash flow from investing activities 	(9) 	125 	(2 844)
Purchase of financial assets 	(8 944) 	(9 803) 	(21 725)
Proceeds from disposal of financial assets 	9 994 	11 392 	21 831
Purchase of property and equipment 	(114) 	(308) 	(510)
Proceeds from disposal of property and equipment 	– 	17 	95
Purchase of software and other intangible assets 	(809) 	(961) 	(1 999)
Proceeds from disposal of intangible assets 	– 	– 	22
Proceeds from disposal of equity-accounted investments 	– 	– 	402
Additional investment in equity-accounted investments 	(152) 	(212) 	(224)
Acquistion of business net of cash 	16 	– 	(736)
Cash flow from financing activities 	749 	1 533 	(344)
Proceeds from issuance of ordinary shares 	– 	1 854 	1 854
Shares issue costs 	– 	(17) 	(19)
Acquisition of additional interest in subsidiary 	– 	– 	(1 104)
Dividends paid to ordinary shareholders 	(748) 	(736) 	(1 400)
Dividends paid to preference shareholders 	(41) 	(40) 	(81)
Proceeds from borrowings 	2 320 	2 133 	2 147
Repayment of borrowings 	(782) 	(1 661) 	(1 741)
Net increase/(decrease) in cash and cash equivalents 	813 	(171) 	(1 450)
Cash and cash equivalents at beginning of the period 	9 403 	10 894 	10 888
Exchange gains/(losses) on cash and cash equivalents 	113 	42 	(35)
Cash and cash equivalents at end of the period 	10 329 	10 765 	9 403
STATEMENT OF CASH FLOWS
for the six months ended 31 December 2019
12	Unaudited interim results and cash dividend declaration December 2019

-- 14 of 42 --

Fair value hierarchy of financial instruments
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three levels that
reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1 includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial instruments.
Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and
those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2 includes financial instruments that are valued using techniques based significantly on observable market data. Instruments in this
category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable market data.
Level 3 includes financial instruments that are valued using valuation techniques that incorporate information other than observable market data
and where at least one input (which could have a significant effect on instruments’ valuation) cannot be based on observable market data.
31 December 2019
R million (Unaudited) 	Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial instruments mandatorily at fair value through profit or loss:
– Equity securities 	34 615 	– 	– 	34 615
– Equity linked notes 	– 	2 720 	– 	2 720
– Debt securities 	24 439 	1 704 	– 	26 143
– Inflation linked securities 	701 	* 	– 	701
– Money market securities 	7 108 	6 847 	– 	13 955
– Mutual funds 	18 568 	– 	– 	18 568
Derivative financial instruments at fair value:
– used for cash flow hedges 	– 	22 	– 	22
– not designated as hedging instruments 	– 	111 	– 	111
85 431 	11 404 	– 	96 835
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	22 749 	– 	22 749
Derivative financial instruments at fair value:
– used for cash flow hedges 	– 	412 	– 	412
– not designated as hedging instruments 	– 	620 	– 	620
– 	23 781 	– 	23 781
* Amount is less than R500 000.
There were no transfers between level 1 and 2 during the current financial period.
ADDITIONAL INFORMATION
at 31 December 2019
13

-- 15 of 42 --

Fair value hierarchy of financial instruments continued
Specific valuation techniques used to value financial instruments in level 2
– Discovery has invested in equity linked notes offered by international banks in order to back certain unit-linked contract liabilities. The
calculation of the daily value of the equity linked investments is made by the provider of the note. Discovery has procedures in place to ensure
that these prices are correct. Aside from the daily reasonableness checks versus similar funds and movement since the prior day’s price, the
fund values are calculated with reference to a specific formula or index, disclosed to the policyholders, which is recalculated by Discovery in
order to check if the price provided by the provider is correct.
– If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial instruments, the
fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of recent arm’s length market
transactions, reference to the current fair value of another instrument that is substantially the same, discounted cash flow techniques, option
pricing models or other valuation techniques that provide a reliable estimate of prices obtained in actual market transactions.
– The fair value of the derivatives is calculated as follows:
(a) The fair value of call options is calculated on a Black-Scholes model.
(b) The fair value of the return swaps is calculated by discounting the future cash flows of the instruments.
(c) The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based on observable yield curves.
30 June 2019
R million (Audited) 	Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial instruments mandatorily at fair value through profit or loss:
– Equity securities 	33 966 	1 015 	– 	34 981
– Equity linked notes 	23 	3 178 	– 	3 201
– Debt securities 	19 531 	1 599 	– 	21 130
– Inflation linked securities 	554 	– 	– 	554
– Money market securities 	7 362 	6 403 	– 	13 765
– Mutual funds 	16 574 	– 	– 	16 574
Derivative financial instruments at fair value:
– used for cash flow hedges 	– 	176 	– 	176
– not designated as hedging instruments 	– 	199 	– 	199
78 010 	12 570 	– 	90 580
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	20 674 	– 	20 674
Derivative financial instruments at fair value:
– used for cash flow hedges 	– 	250 	– 	250
– not designated as hedging instruments 	– 	259 	– 	259
– 	21 183 	– 	21 183
ADDITIONAL INFORMATION continued
at 31 December 2019
14	Unaudited interim results and cash dividend declaration December 2019

-- 16 of 42 --

Exchange rates used in the preparation of these results
USD 	GBP
31 December 2019
– Average 	14.71 	18.53
– Closing 	14.07 	18.50
30 June 2019
– Average 	14.17 	18.32
– Closing 	14.15 	17.98
31 December 2018
– Average 	14.17 	18.27
– Closing 	14.39 	18.33
15

-- 17 of 42 --

SEGMENTAL INFORMATION
for the six months ended 31 December 2019
R million
SA
Health
SA
Life
SA
Invest
SA
Vitality
Income statement
Insurance premium revenue 	114 	6 419 	7 001 	–
Reinsurance premiums 	(1) 	(1 247) 	– 	–
Net insurance premium revenue 	113 	5 172 	7 001 	–
Fee income from administration businesses 	3 525 	– 	1 121 	–
Vitality income 	– 	– 	– 	1 187
Other income 	433 	24 	– 	–
Banking interest and similar income 	– 	– 	– 	–
Investment income earned on assets backing policyholder liabilities 	– 	22 	– 	–
Finance charge on negative reserve funding 	– 	– 	– 	–
Inter-segment funding1 	– 	(383) 	383 	–
Net fair value gains on financial assets at fair value through profit or loss 	– 	366 	1 685 	–
Net income 	4 071 	5 201 	10 190 	1 187
Claims and policyholders’ benefits 	(45) 	(4 118) 	(5 402) 	–
Insurance claims recovered from reinsurers 	– 	970 	– 	–
Net claims and policyholders’ benefits 	(45) 	(3 148) 	(5 402) 	–
Acquisition costs 	(5) 	(881) 	(582) 	(43)
Bank interest and similar expenses 	– 	– 	– 	–
Credit impairment charges 	– 	– 	– 	–
Marketing and administration expenses
– depreciation and amortisation 	(93) 	(3) 	(4) 	(7)
– impairment 	– 	– 	– 	(2)
– other expenses 	(2 355) 	(1 026) 	(479) 	(1 130)
Recovery of expenses from reinsurers 	– 	– 	– 	–
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	1 724 	– 	–
– change in assets arising from reinsurance contracts 	– 	10 	– 	–
– change in liabilities arising from insurance contracts 	1 	44 	(3 073) 	–
– change in liabilities arising from reinsurance contracts 	– 	(45) 	– 	–
Fair value adjustment to liabilities under investment contracts 	– 	(1) 	(165) 	–
Share of net profits from equity-accounted investments 	1 	– 	– 	–
Normalised profit/(loss) from operations 	1 575 	1 875 	485 	5
Investment income earned on shareholder investments and cash 	29 	9 	25 	9
Net fair value gains on financial assets at fair value through profit or loss 	– 	87 	5 	–
Impairment of goodwill 	– 	– 	– 	–
Initial expenses related to Prudential Book transfer 	– 	– 	– 	–
Transaction costs related to VitalityLife interest rate derivatives 	– 	– 	– 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	–
Market rentals related to Head Office building adjusted for finance costs
and depreciation 	– 	– 	– 	–
Finance costs 	(4) 	– 	– 	–
Foreign exchange gains 	2 	– 	3 	–
Profit before tax 	1 602 	1 971 	518 	14
Income tax expense 	(378) 	(556) 	(145) 	(4)
Profit for the period 	1 224 	1 415 	373 	10
1 The inter-segment funding of R383 million reflects a notional allocation of interest earned on the negative reserve backing policyholders' funds of guaranteed investment products
and hence is transferred to Discovery Invest.
16	Unaudited interim results and cash dividend declaration December 2019

-- 18 of 42 --

IFRS reporting adjustments
UK
Health
UK
Life
All other
segments
Segment
total
UK
Life 2 	DUT3
Disclosure
adjustments4
IFRS
total
4 569 	2 620 	2 998 	23 721 	(343) 	– 	– 	23 378
(787) 	(1 254) 	(55) 	(3 344) 	343 	– 	– 	(3 001)
3 782 	1 366 	2 943 	20 377 	– 	– 	– 	20 377
16 	– 	908 	5 570 	– 	– 	(6) 	5 564
270 	98 	452 	2 007 	– 	– 	– 	2 007
22 	– 	153 	632 	– 	– 	(15) 	617
– 	– 	48 	48 	– 	– 	– 	48
5 	23 	64 	114 	– 	– 	(114) 	–
– 	(113) 	– 	(113) 	113 	– 	– 	–
– 	– 	– 	– 	– 	– 	– 	–
20 	(146) 	88 	2 013 	– 	584 	61 	2 658
4 115 	1 228 	4 656 	30 648 	113 	584 	(74) 	31 271
(2 549) 	(905) 	(1 122) 	(14 141) 	204 	– 	(13 937)
618 	582 	16 	2 186 	(204) 	– 	– 	1 982
(1 931) 	(323) 	(1 106) 	(11 955) 	– 	– 	– 	(11 955)
(404) 	(928) 	(178) 	(3 021) 	(113) 	– 	– 	(3 134)
– 	– 	(26) 	(26) 	– 	– 	– 	(26)
– 	– 	(36) 	(36) 	– 	– 	– 	(36)
(147) 	(21) 	(433) 	(708) 	– 	– 	(105) 	(813)
– 	– 	– 	(2) 	– 	– 	– 	(2)
(1 641) 	(1 021) 	(2 543) 	(10 195) 	(6) 	(127) 	121 	(10 207)
436 	1 076 	– 	1 512 	– 	– 	– 	1 512
– 	377 	– 	2 101 	483 	– 	– 	2 584
(12) 	5 	– 	3 	(483) 	– 	– 	(480)
79 	(8) 	(1 188) 	(4 145) 	(1) 	(36) 	– 	(4 182)
– 	(519) 	– 	(564) 	1 	– 	– 	(563)
– 	– 	(20) 	(186) 	– 	(421) 	23 	(584)
– 	– 	124 	125 	– 	– 	– 	125
495 	(134) 	(750) 	3 551 	(6) 	– 	(35) 	3 510
1 	8 	20 	101 	– 	– 	114 	215
– 	– 	(8) 	84 	– 	– 	(84) 	–
– 	– 	(9) 	(9) 	– 	– 	– 	(9)
– 	(18) 	– 	(18) 	– 	– 	18 	–
– 	(24) 	– 	(24) 	– 	– 	24 	–
– 	– 	(36) 	(36) 	– 	– 	– 	(36)
– 	– 	(137) 	(137) 	– 	– 	137 	–
(4) 	(2) 	(571) 	(581) 	– 	– 	(174) 	(755)
– 	– 	39 	44 	– 	– 	– 	44
492 	(170) 	(1 452) 	2 975 	(6) 	– 	– 	2 969
(58) 	27 	217 	(897) 	6 	– 	– 	(891)
434 	(143) 	(1 235) 	2 078 	– 	– 	– 	2 078
The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then adjusted for accounting
reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
2 The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual arrangement as a reinsurance contract
under IFRS 4.
3 The Discovery Unit Trusts (DUT) are consolidated into Discovery's results for IFRS purposes. In the Segment information the DUT column includes the effects of consolidating the
unit trusts into Discovery's results, effectively being the income and expenses relating to units held by third parties.
4 The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
17

-- 19 of 42 --

SEGMENTAL INFORMATION continued
for the six months ended 31 December 2018
R million
SA Health
Restated 1
SA Life
Restated 1
SA
Invest
SA
Vitality
Income statement
Insurance premium revenue 	26 	5 947 	7 476 	–
Reinsurance premiums 	(1) 	(1 224) 	– 	–
Net insurance premium revenue 	25 	4 723 	7 476 	–
Fee income from administration businesses2 	3 320 	– 	1 008 	–
Vitality income2 	– 	– 	– 	1 126
Other income2 	393 	20 	– 	78
Investment income on assets backing policyholder liabilities3 	– 	(3) 	33 	–
Finance charge on negative reserve funding 	– 	– 	– 	–
Inter-segment funding4 	– 	(403) 	403 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss3 	8 	468 	(1 717) 	1
Net income 	3 746 	4 805 	7 203 	1 205
Claims and policyholders’ benefits 	(3) 	(4 094) 	(4 456) 	–
Insurance claims recovered from reinsurers 	– 	1 132 	– 	–
Net claims and policyholders’ benefits 	(3) 	(2 962) 	(4 456) 	–
Acquisition costs 	(3) 	(905) 	(579) 	(44)
Marketing and administration expenses
– depreciation and amortisation 	(118) 	(2) 	(2) 	(4)
– impairment of intangible assets 	– 	– 	– 	–
– other expenses 	(2 160) 	(918) 	(443) 	(1 137)
Recovery of expenses from reinsurers 	– 	– 	– 	–
Net transfer to/from assets and liabilities under insurance contracts 	– 	–
– change in assets arising from insurance contracts 	– 	1 610 	– 	–
– change in assets arising from reinsurance contracts 	– 	4 	– 	–
– change in liabilities arising from insurance contracts 	– 	(108) 	(1 388) 	–
– change in liabilities arising from reinsurance contracts 	– 	(23) 	– 	–
Fair value adjustment to liabilities under investment contracts 	– 	(1) 	120 	–
Share of net profits/(losses) from equity accounted investments 	2 	– 	– 	–
Normalised profit/(loss) from operations 	1 464 	1 500 	455 	20
Investment income earned on shareholder investments and cash3 	31 	3 	18 	18
Net fair value gains/(losses) on financial assets at fair value through profit or loss3 	– 	48 	(12) 	–
Gains from dilution of equity accounted investments 	– 	– 	– 	–
Initial expenses related to Prudential Book transfer 	– 	– 	– 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	–
Market rentals related to Head Office building adjusted for finance costs
and depreciation 	– 	– 	– 	–
Finance costs 	(6) 	(2) 	– 	–
Foreign exchange gains/losses 	– 	– 	5 	–
Profit before tax 	1 489 	1 549 	466 	38
Income tax expense 	(388) 	(395) 	(132) 	(11)
Profit for the period 	1 101 	1 154 	334 	27
1 The restatements are as a result of reclassifications. The reclassifications had no effect on the reported ‘Net income’, ‘Profit for the period’ or associated earnings per share values.
The restatements do not affect any financial information published in the Annual Financial Statements for the year ended 30 June 2019. Refer to note ‘Restatement due to incorrect
prior period classification’.
2 Refer to footnote 1. ‘Fee income from administration businesses’ was increased by R263 million, ‘Vitality income’ was reduced by R464 million and ‘Other income’ was increased
by R201 million.
3 Refer to footnote 1. ‘Investment income earned on assets backing policyholder liabilities’ was reduced by R167 million and ‘Net fair value gains/(losses) on financial assets at fair
value through profit or loss’ was increased by R167 million. ‘Investment income earned on shareholder investments and cash’ was reduced by R152 million and ‘Net fair value
gains/(losses) on financial assets at fair value through profit or loss’ was increased by R152 million.
4 The inter-segment funding of R403 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment products
and hence is transferred to Discovery Invest.
18	Unaudited interim results and cash dividend declaration December 2019

-- 20 of 42 --

IFRS reporting adjustments
UK
Health
UK
Life
All other
segments
Restated 1
Segment
total
UK
Life5 	DUT6
Disclosure
adjustments7
IFRS
total
Restated1
4 134 	2 312 	1 744 	21 639 	(338) 	– 	– 	21 301
(663) 	(1 028) 	(163) 	(3 079) 	338 	– 	– 	(2 741)
3 471 	1 284 	1 581 	18 560 	– 	– 	– 	18 560
10 	– 	544 	4 882 	– 	– 	(9) 	4 873
239 	68 	513 	1 946 	– 	– 	– 	1 946
– 	– 	121 	612 	– 	– 	(10) 	602
6 	17 	86 	139 	– 	– 	(139) 	–
– 	19 	– 	19 	(19) 	– 	– 	–
– 	– 	– 	– 	– 	– 	– 	–
(5) 	(32) 	(8) 	(1 285) 	– 	(462) 	(19) 	(1 766)
3 721 	1 356 	2 837 	24 873 	(19) 	(462) 	(177) 	24 215
(2 222) 	(494) 	(891) 	(12 160) 	149 	– 	(12 011)
529 	250 	72 	1 983 	(149) 	– 	– 	1 834
(1 693) 	(244) 	(819) 	(10 177) 	– 	– 	– 	(10 177)
(324) 	(960) 	(157) 	(2 972) 	19 	– 	– 	(2 953)
– 	–
(120) 	(17) 	(203) 	(466) 	– 	– 	(105) 	(571)
– 	– 	(18) 	(18) 	– 	– 	– 	(18)
(1 520) 	(986) 	(1 909) 	(9 073) 	(34) 	(121) 	132 	(9 096)
388 	968 	37 	1 393 	– 	– 	– 	1 393
– 	–
– 	786 	– 	2 396 	134 	– 	– 	2 530
(23) 	5 	– 	(14) 	4 	– 	– 	(10)
17 	(8) 	(212) 	(1 699) 	(4) 	21 	87 	(1 595)
– 	(600) 	– 	(623) 	(134) 	– 	– 	(757)
– 	– 	– 	119 	– 	562 	22 	703
– 	– 	58 	60 	– 	– 	– 	60
446 	300 	(386) 	3 799 	(34) 	– 	(41) 	3 724
1 	6 	18 	95 	– 	– 	139 	234
– 	– 	(36) 	– 	– 	– 	– 	–
– 	– 	51 	51 	– 	– 	– 	51
– 	(14) 	(2) 	(16) 	– 	– 	16 	–
– 	– 	(61) 	(61) 	– 	– 	– 	(61)
– 	– 	(142) 	(142) 	– 	– 	142 	–
– 	(2) 	(502) 	(512) 	– 	– 	(169) 	(681)
– 	– 	1 	6 	– 	– 	– 	6
447 	290 	(1 059) 	3 220 	(34) 	– 	87 	3 273
(40) 	(45) 	117 	(894) 	34 	– 	(87) 	(947)
407 	245 	(942) 	2 326 	– 	– 	– 	2 326
The segment information is presented on the same basis as reported to the Chief Executive Officers of the reportable segments. The segment total is then adjusted for accounting
reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
5 The VitalityLife results, for business written on the Prudential Assurance Company license, are reclassified to account for the contractual arrangement as a reinsurance contract
under IFRS 4.
6 The Discovery Unit Trusts (DUT) are consolidated into Discovery’s results for IFRS purposes. In the Segment information the DUT column includes the effects of consolidating
the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties.
7 The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
19

-- 21 of 42 --

REVIEW OF GROUP RESULTS
for the six months ended 31 December 2019
New business annualised premium income
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of the
Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, Discovery Health
Medical Scheme’s (DHMS) new business is attributable to the medical scheme but is under the administration and marketing of Discovery Health
which earns a fee in respect of such services.
Core new business API increased by 5% for the six months ended 31 December 2019 when compared to the same period in the prior year.
R million
December
2019
December
2018
%
change
Discovery Health1 	3 289 	3 437 	(4)
Discovery Life 	1 240 	1 212 	2
Discovery Invest 	1 357 	1 387 	(2)
Discovery Vitality 	71 	80 	(11)
Discovery Insure 	551 	517 	7
VitalityHealth 	613 	616 	–
VitalityLife 	646 	600 	8
Ping An Health (25% interest) 	1 382 	1 080 	28
Other new businesses2 	374 	137 	173
Core new business API of Group 	9 523 	9 066 	5
New Closed Schemes1 	1 078 	18 	>999
New business API of Group including New Closed Schemes 	10 601 	9 084 	17
Gross revenue Vitality Group3 	515 	441 	17
Total new business API and other new business 	11 116 	9 525 	17
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings such as GAP
cover and Primary Care cover. The comparative has been restated by R17 million to include new business API from GAP cover. The new business API for New Closed Schemes
includes contracted new business API and business in the first twelve months of on-boarding. Closed Schemes refer to those restricted to certain employers and industries.
2 Other new businesses include the Umbrella Fund, Discovery Insure commercial and VitalityInvest.
3 Vitality Group new business includes gross recurring and lump sum revenues earned by Vitality Group and specifically excludes revenue related to cost recoveries and rewards.
Calculation of new business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single
premium policies. It also includes both automatic premium increases and servicing increases on existing long-term insurance policies.
The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of:
– The timing of inclusion of policyholders in the calculation of new business API – In the embedded value, new business is included from the
earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above, new business is
included when the policy has been contractually committed.
– Inclusion of automatic premium increases and servicing increases on existing life policies – These are included in the table above but excluded in
the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business
disclosures between the embedded value and the table above.
20	Unaudited interim results and cash dividend declaration December 2019

-- 22 of 42 --

Gross inflows under management
Gross inflows under management measures the total funds collected by Discovery. Gross inflows under management increased by 11% for the
six months ended 31 December 2019 when compared to the same period in the prior year.
R million
December
2019
December
2018
%
change
Discovery Health 	43 099 	39 405 	9
Discovery Life 	6 443 	5 967 	8
Discovery Invest 	11 939 	11 280 	6
Discovery Insure 	1 766 	1 558 	13
Discovery Vitality 	1 187 	1 204 	(1)
VitalityHealth 	4 877 	4 383 	11
VitalityLife 	2 718 	2 380 	14
All other businesses 	2 745 	1 364 	101
Gross inflows under management 	74 774 	67 541 	11
Less: collected on behalf of third parties 	(42 844) 	(38 462) 	11
Discovery Health 	(39 027) 	(35 666) 	9
Discovery Invest 	(3 817) 	(2 796) 	37
Gross income of Group per the segmental information 	31 930 	29 079 	10
Gross income is made up as follows:
– Insurance premium revenue 	23 721 	21 639 	10
– Fee income from administration businesses 	5 570 	4 882 	14
– Vitality income 	2 007 	1 946 	3
– Other income 	632 	612 	3
Gross income of Group per the segmental information 	31 930 	29 079 	10
21

-- 23 of 42 --

REVIEW OF GROUP RESULTS continued
for the six months ended 31 December 2019
Normalised profit from operations
The following table shows the main components of the normalised profit from operations for the six months ended 31 December 2019:
R million
December
2019
December
2018
%
change
Discovery Health 	1 575 	1 464 	8
Discovery Life 	1 875 	1 500 	25
Discovery Invest 	485 	455 	7
Discovery Vitality 	5 	20 	(75)
VitalityHealth 	495 	446 	11
VitalityLife 	(134) 	300 	(145)
Normalised profit from established businesses 	4 301 	4 185 	3
Emerging businesses 	253 	169 	50
– Discovery Insure 	75 	62 	21
– Vitality Group including Ping An Health 	178 	107 	66
Normalised profit from operations before investment in new initiatives 	4 554 	4 354 	5
Development and other segments 	(1 003) 	(555) 	(81)
Normalised profit from operations 	3 551 	3 799 	(7)
Emerging businesses are those businesses that have achieved sufficient scale to be profitable or profitable in the near future, although not
yet significant in cash generation for the Group and likely to require funds to support new business growth. These businesses are
approximately 5 years or more into their launch. Discovery Insure, excluding commercial insurance, and Vitality Group have been disclosed
as Emerging businesses.
Development and other segments include costs of start-up businesses and expenses incurred to investigate, research and develop new
products and markets. Start-up costs include costs in relation to, amongst others, Discovery Bank, VitalityInvest, a commercial offering in
Discovery Insure, an Umbrella Fund and the Vitality1 platform being a leading behavioural change platform enabling shared-value insurance and
financial services products across the Discovery Group.
Significant transactions affecting the current results
Derivative instruments – VitalityLife business
VitalityLife, as a long-term insurance provider in the United Kingdom (UK), has significant exposure to long-term interest rate risk, given the
impact on reserves of lower investment rate assumptions related to future premium receipts to meet policy obligations. Accordingly, lower
long-term interest rates and yield assumptions may negatively impact on the valuation of future policy obligations and result in a valuation loss.
Interest rates in the UK have displayed significant volatility and have generally been on a downward trend in recent years. In the period under
review, VitalityLife implemented an interest rate risk mitigation strategy to protect itself against further declines in interest rates by entering into
derivative contracts. This strategy ensures that the VitalityLife business operates well within its pre-determined risk appetite.
The derivative instruments comprise of:
– an interest rate swap with a nominal value of GBP 350 million (R6 474 million), which swaps exposure to variable interest rates in return for
a fixed interest rate referenced to the 25 year UK swap rate as at 25 October 2019 (‘reference swap rate’). The interest rate swap is in place
for an extended period of time; and
– a put swap option (payer swaption) which was acquired at a premium of GBP 6.2 million (R115 million) and gives Discovery the participation in
the benefit should interest rates rise by more than 0.45% above the hedged rate. The swaption expires on 27 July 2020.
22	Unaudited interim results and cash dividend declaration December 2019

-- 24 of 42 --

Due to the nature of the underlying exposures, the hedge accounting requirements of IFRS were not met. Therefore, these two derivative
instruments were classified at fair value with changes recognised in profit or loss throughout the term which may result in volatility in the
reported IFRS earnings of VitalityLife. As at 31 December 2019, the following mark-to-market positions were recorded:
Line item in financial statements 	December 2019
Statement of Financial Position
Interest rate swap valuation 	Financial liabilities: Derivative – financial instruments
at fair value through profit or loss 	GBP 12.4 million (R229 million)
Swaption valuation 	Financial assets: Derivative – financial instruments
at fair value through profit or loss 	GBP 5.6 million (R104 million)
Original premium 	GBP 6.2 million (R115 million)
Fair value remeasurement loss 	(GBP 0.6 million) ((R11 million))
Income Statement
Fair value remeasurement loss 	Net fair value gains/(losses) on financial assets
at fair value through profit or loss 	GBP 13 million (R241 million)
Transaction costs 	Marketing and administration expenses1 	GBP 1.3 million (R24 million)
1 Reflected as part of the normalisation adjustments in the results.
From an economic perspective, VitalityLife effectively fixed the reference swap rate as at 25 October 2019 (being 0.96%). In doing so, VitalityLife
limited its exposure to approximately GBP 40 million (R740 million) as a result of the valuation of specified future policy obligations. This
estimate excludes the cost of option premiums and ignores any potential basis risk. It is important to note that at 31 December 2019, Discovery
has not adjusted its insurance contract discount interest rate assumption from 30 June 2019 levels.
Borrowings at amortised cost
R million 	Reference
December
2019
June
2019
Borrowings from Banks and listed debt 	12 780 	11 034
– United Kingdom borrowings 	i 	1 520 	1 612
– South African borrowings 	ii 	11 260 	9 422
Lease liabilities 	4 393 	3 648
– 1 Discovery Place 	3 353 	3 321
– Other lease liabilities 	iii 	1 041 	327
Total borrowings at amortised cost 	17 174 	14 682
i. 	United Kingdom borrowings
Discovery previously entered into term facilities totalling GBP 150 million. These borrowings have been used to fund the new business
acquisition costs incurred by VitalityLife, which were previously funded by The Prudential Assurance Company Limited (Prudential).
Discovery repaid GBP 60 million of this facility in previous financial periods and a further repayment of GBP 7.5 million of this facility
in November 2019. The balance owing at 31 December 2019 amounts to GBP 82 million (R1 520 million) (30 June 2019: GBP 90 million
(R1 612 million)).
These facilities carry interest at floating 3-month LIBOR, payable quarterly in arrears. Finance costs of R20 million (31 December 2018:
R21 million) in respect of these borrowings have been recognised in profit or loss.
ii. South African borrowings
R million 	Reference
December
2019
June
2019
Balance at beginning of the period 	9 422 	7 240
Issuance of listed debt 	a. 	1 520 	700
Draw down on existing and new bank facilities 	b. 	800 	1 447
Repayment of borrowings 	b. 	(517) 	(30)
Accrued interest 	35 	68
– Finance costs capitalised to intangible assets 	– 	47
– Finance costs expensed to profit or loss 	477 	787
– Finance costs paid 	(442) 	(766)
Raising fees capitalised 	– 	(4)
Net foreign exchange differences 	– 	1
Balance at end of the period 	11 260 	9 422 23

-- 25 of 42 --

REVIEW OF GROUP RESULTS continued
for the six months ended 31 December 2019
Significant transactions affecting the current results
continued
Borrowings at amortised cost continued
Moody’s reaffirmed a Aa3.za issuer rating to Discovery Limited
on 16 December 2019.
a. 	Discovery registered an unsecured R10 billion Domestic
Medium Term Note (DMTN) programme in November 2017.
In terms of this programme, Discovery had issued a
cumulative amount of R2.2 billion in JSE Listed Notes to 30
June 2019. Discovery further issued 5 year and 7 year
Floating Rate Notes of R1.2 billion and R300 million
respectively on 26 November 2019, with coupon interest
rates of 8.85% per annum and 9.35% per annum
respectively, fixed through interest rate swaps. Interest is
payable quarterly in arrears and capital is payable in full at
maturity date.
b. During the period, Discovery Bank Limited, a subsidiary of
the Discovery Group, entered into a R1 billion 2 year facility
as part of its operational treasury management function to
support its loans and advances book. Discovery Limited,
Discovery Health (Pty) Limited and Discovery Vitality (Pty)
Limited provided a joint guarantee in respect of R500
million of this facility. As at 31 December 2019, R300 million
of this facility was drawn at variable interest rates linked to
3-month JIBAR, payable quarterly in arrears.
During the period, Discovery Central Services (Pty) Limited,
a subsidiary of the Discovery Group, entered into short-
term revolving credit facilities of R500 million as part of its
ongoing operational activities. The short-term revolving
credit facilities were fully repaid as at 31 December 2019. In
the previous financial year, Discovery Central Services,
entered into new unsecured 5 year loan facilities of
R1.4 billion as part of a broader debt refinancing
programme. Interest on this facility is fixed at 10.60% per
annum. Interest is payable quarterly in arrears and capital
is repayable in full at maturity on 20 December 2023.
Finance costs of R513 million (31 December 2018: R378 million)
in respect of South African borrowings and related hedges have
been recognised in profit or loss.
iii. Other lease liabilities
Refer to ‘New accounting standards’ for the impact of the first
time adoption of IFRS 16 Leases, adopted by Discovery from 1
July 2019.
Other significant items in these results
Deferred tax
With the promulgation of the South African Insurance Act 18 of 2017,
the new ‘adjusted IFRS’ tax basis has been effective since 1 July 2018
for Discovery Life. Deferred tax has been provided for on the
difference between the IFRS and tax liabilities to the extent that
timing differences arise. A deferred tax liability of R9 154 million
relates to assets and liabilities arising from insurance contracts.
Consolidation of Discovery Unit Trusts
The Discovery Unit Trusts are consolidated into Discovery’s results
for accounting purposes, which results in the recognition of the
underlying assets and liabilities of each of the funds.
Assets and liabilities of the Discovery Unit Trusts increased by
R189 million respectively, compared to the prior financial year with
movements in the following line items on the Group’s Statement of
Financial Position:
Changes in assets
– Investments at fair value through profit or loss increased by
R877 million.
– Cash and cash equivalents decreased by R651 million.
– Other assets decreased by R37 million.
Changes in liabilities
– Investment contracts at fair value through profit or loss increased
by R130 million.
– Trade and other payables increased by R108 million.
– Other liabilities decreased by R49 million.
As these policies are linked, the consolidation of the Discovery Unit
Trusts has no impact on the net asset value for shareholders.
There are significant trade volumes in the underlying funds of
Discovery Unit Trusts. The cash flow impact of the movement in
policyholder investments for the period is included in the following
line items on the Group’s Statement of Cash Flows:
– Purchase of investments held to back policyholder liabilities
includes cash outflows of R2.1 billion.
– Proceeds from the disposal of investments held to back policyholder
liabilities includes cash inflows of R1.3 billion.
Material transactions with related parties
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed care
services for which it charges an administration fee and a managed
healthcare fee respectively. These fees are determined on an annual
basis and approved by the trustees of DHMS. The fees totalled
R3 020 million for the six months ended 31 December 2019 (2018:
R2 856 million). Discovery offers the members of DHMS access to the
Vitality programme.
Equity issued to related parties
Per the Discovery Limited’s long-term incentive plan, which was
approved by shareholders at the annual general meeting held on
28 November 2019, the awards accepted by executive directors and
prescribed officers amount to a deemed transaction value of
R29 million and R28 million respectively. These will vest from between
the third and fifth anniversary of the awards (between 1 October 2022
and 1 October 2024), provided the necessary vesting criteria have
been achieved. Details of this have previously been disclosed on
24 December 2019, by way of an announcement on SENS.
24	Unaudited interim results and cash dividend declaration December 2019

-- 26 of 42 --

Shareholder information
Directorate
Changes to the Board of Discovery Limited from 1 July 2019 to the
date of this announcement are as follows:
– Mr HP Mayers, moved from an executive director role to a non-
executive director role effective 28 November 2019, following a
period of medical leave.
– Mr D Macready has been appointed as an independent non-
executive director with effect from 3 February 2020.
– Mr AL Owen, an independent non-executive director, retired,
effective 14 February 2020.
Changes in executive director responsibilities from 1 July 2019 to the
date of this announcement are as follows:
– Mr NS Koopowitz, Chief Executive Officer (CEO) of VitalityHealth,
became CEO of the Vitality UK Group, effective 28 November 2019.
This will create a single point of accountability for delivery of the
composite model, as well as a number of Group functions that
span across both VitalityHealth and VitalityLife in key areas.
– Mr HD Kallner, CEO of Discovery Life, assumed the role of CEO of
Discovery’s South African operations effective 29 January 2020. In
the role, Mr Kallner will lead the composite strategy for Health, Life,
Invest, Insure, and Vitality entities, and will oversee their integration
with Vitality and Discovery Bank. Mr Kallner will continue to chair
the SA Executive Committee, as the core governance forum of the
SA composite.
Dividend and capital
Final dividends paid in respect of the 2019 financial year
The following final dividends were paid during the current period:
– B preference share dividend of 508.28767 cents per share
(406.63014 cents net of dividend withholding tax), paid on
23 September 2019.
– Ordinary share dividend of 114 cents per share (91.2 cents net of
dividend withholding tax), paid on 7 October 2019.
Interim dividend declaration in respect of the 2020 financial year
B preference share cash dividend declaration:
On 14 February 2020 the directors declared an interim gross cash
dividend of 505.41097 cents (404.32878 cents net of dividend
withholding tax) per B preference share for the period 1 July 2019 to
31 December 2019, payable from the income reserves of the
Company. A dividend withholding tax of 20% will be applicable to all
shareholders who are not exempt.
The issued preference share capital at the declaration date is
8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 10 March 2020
Shares commence trading “ex” dividend Wednesday, 11 March 2020
Record date 	Friday, 13 March 2020
Payment date 	Monday, 16 March 2020
B preference share certificates may not be dematerialised or
rematerialised between Wednesday, 11 March 2020 and Friday,
13 March 2020, both days inclusive.
Ordinary share cash dividend declaration:
Notice is hereby given that the directors have declared an interim
gross cash dividend of 101 cents (80.8 cents net of dividend
withholding tax) per ordinary share, out of income reserves for the
six month period ended 31 December 2019. A dividend withholding
tax of 20% will be applicable to all shareholders who are not exempt.
The issued ordinary share capital at the declaration date is
658 290 736 ordinary shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 17 March 2020
Shares commence trading “ex” dividend 	Wednesday, 18 March 2020
Record date 	Friday, 20 March 2020
Payment date 	Monday, 23 March 2020
Share certificates may not be dematerialised or rematerialised
between Wednesday, 18 March 2020 and Friday, 20 March 2020,
both days inclusive.
Capital
For Group subsidiaries that operate in the insurance and financial
services sectors, the relevant regulator specifies the minimum amount
and type of capital that must be held by each of the subsidiaries in
addition to their insurance liabilities. The minimum required capital
must be maintained at all times throughout the period.
With effect from 1 July 2018, the Insurance Act 18 of 2017 (Insurance
Act), and the related Prudential Standards were implemented in South
Africa. Discovery Life and Discovery Insure are regulated under the
Insurance Act, while Vitality Health and Vitality Life are regulated under
the European Solvency II regulatory regime, which was implemented
from 1 January 2016.
The table below summarises the capital requirements on the
statutory basis, across the Group subsidiaries, and the actual
solvency capital held in relation to this requirement.
December 2019
Statutory capital requirements 	Cover
June 2019
Statutory capital requirements 	Cover
Discovery Life 	R16 278 million 	1.7 times 	R17 396 million 	1.6 times
Discovery Insure 	R846 million 	1.7 times 	R789 million 	1.7 times
Vitality Health 	GBP 97 million (R1 789 million) 	1.4 times 	GBP 97 million (R1 777 million) 	1.4 times
Vitality Life 	GBP 190 million (R3 526 million) 	1.7 times 	GBP 208 million (R3 810 million) 	1.5 times
25

-- 27 of 42 --

Accounting policies
The interim results have been prepared in accordance with
International Financial Reporting Standards (IFRS) including IAS 34
Interim Financial Reporting, the SAICA Financial Reporting Guides as
issued by the Accounting Practices Committee and Financial
Pronouncements as issued by the Financial Reporting Standards
Council as well as the requirements of the South African Companies
Act 71 of 2008. The accounting policies adopted are consistent with
the accounting policies applied in the prior Annual Financial
Statements, except for the policies described below.
Discovery has adopted IFRS 16 Leases from 1 July 2019. Other
amendments and annual improvements to IFRS effective for 1 July 2019
have also been adopted but do not have an impact on Discovery’s
reported results.
As permitted by the transitional provisions of IFRS 16, Discovery has
not restated prior year comparative financial statements. Retrospective
adjustments arising from the application of this standard are not
included in the financial statement balances at 30 June 2019, but
have been adjusted to the opening balances at 1 July 2019. The note
below presents the required transitional disclosures required to
understand the changes arising from the adoption of IFRS 16.
New accounting standards
IFRS 16 Leases
Background
IFRS 16 replaces IAS 17 Leases, as well as the related interpretations.
The core principle of IFRS 16 is that the lessee should recognise all
rights and obligations arising from leasing arrangements in its
Statement of Financial Position. The most significant change to
Discovery pertains to the accounting treatment for those leases that
were classified as operating leases from Discovery’s perspective as
the lessee.
IFRS 16 eliminates the classification of leases for lessees as either
operating or finance leases as per IAS 17. Instead, IFRS 16 introduces
a single lessee accounting model, where a right of use (ROU) asset
together with a lease liability for the future payments is recognised
for all leases with a term of more than 12 months, unless the
underlying asset is of a low value. Where Discovery is the lessee, it
has elected, in accordance with IFRS 16, not to apply the lessee
accounting model where the lease is a short-term lease. Short-term
leases have a lease term of 12 months or less and does not include
a renewal option. The rental payments for short-term leases are
expensed on a straight-line basis over the lease term.
IFRS 16 does not introduce significant changes for lessors, or to
those leases previously classified as finance leases from the lessee’s
perspective, and as a result the accounting policies for these
transactions had no material change.
Adoption and transition
On adoption of IFRS 16, Discovery applied the modified retrospective
approach to transition on 1 July 2019. This approach requires the
cumulative effect of initially applying IFRS 16 as an adjustment to the
opening reserves at 1 July 2019. As required by IFRS 16, Discovery did
not restate its comparative financial results. Accordingly:
– Discovery’s previously reported financial results up to 30 June 2019
are presented in accordance with the requirements of IAS 17; and
– From 1 July 2019 Discovery’s financial results are presented in
terms of IFRS 16.
REVIEW OF GROUP RESULTS continued
for the six months ended 31 December 2019
On adoption of IFRS 16, Discovery recognised lease liabilities in
relation to leases which had previously been classified as operating
leases under the principles of IAS 17. These liabilities were measured
at the present value of the remaining lease payments, discounted
using the lessee’s incremental borrowing rate as at 1 July 2019. The
incremental borrowing rates were calculated for each legal entity
within the Group that entered into lease arrangements. The
incremental borrowing rate considers a base interest rate reflective
of the jurisdiction in which the legal entity operates (South Africa,
United Kingdom and United States of America), the term of the lease
arrangement and the nature of the assets.
ROU assets were measured retrospectively at the amount equal to
the lease liability at the commencement of the lease, using the
discount rate as determined on 1 July 2019 for the lease liability, and
depreciated from commencement date up until 30 June 2019.
The resulting difference between the lease liability and the ROU
asset as at 1 July 2019 is recognised as an adjustment to the opening
retained earnings. In addition, any previously recognised rights (e.g.
prepaid rentals) or obligations (e.g. straight-line accruals) are also
derecognised as adjustments to the opening retained earnings on
1 July 2019.
Practical expedients applied
In applying IFRS 16 for the first time, Discovery used the following
practical expedients permitted by IFRS 16:
– accounting for leases with a remaining lease term of less than
12 months as at 1 July 2019, as short-term leases, provided there
was no option to extend the term. For short-term rentals, the lessee
recognises the payments as an expense on a straight-line basis;
– the use of a single discount rate for a specified portfolio of leases
that have reasonably similar characteristics;
– the exclusion of initial direct costs for the measurement of the ROU
asset at the date of initial application; and
– the use of hindsight in determining the lease term where the
contract contains options to extend or terminate the lease.
Identifying leases, low value assets and leasing activities
Effective 1 July 2019, all leases, which either had a term not less than
12 months or not deemed a low value asset, were recognised as a
ROU asset and a corresponding lease liability.
Discovery leases the following assets with a range of lease terms:
– Large offices 	5 – 15 years
– Small offices/Franchise offices (SA only) 	1 – 3 years
– Computer equipment (e.g. servers) (SA only) 	3 – 4 years
– Motor vehicles (UK only) 	3 years
Leases of low value assets relate to those categories of assets which
at inception of the lease typically have a value, if bought new, of no
more than approximately R70 000. For Discovery, these categories
include computer equipment such as desktops, laptops, monitors
and related IT peripherals.
Contracts where the service provider has a substantive right to
substitute the asset for an alternative asset during the lease term is
not regarded as a lease, but instead a service contract. Accordingly,
these contracts are not accounted for in accordance with IFRS 16.
For Discovery, such contracts include items such as vending
machines.
26	Unaudited interim results and cash dividend declaration December 2019

-- 28 of 42 --

Extension or termination options
Extension or termination options are included in a number of the building leases across the Group. These terms are used to maximise
operational flexibility in terms of managing contracts. In determining the lease term, management considers all facts and circumstances that
create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options (or periods after
termination options) are considered in the lease term when there is reasonable certainty that those options will be exercised.
Effect of changes in IFRS 16 on date of initial application
At 1 July 2019
R million
Group
30 June
2019
Previously
reported
Audited
IFRS 16
Adjustments
Group
1 July
2019
Restated
Assets
Property and equipment 	4 212 	667 	4 879
Total impact on assets 	667
Equity
Retained earnings 	31 710 	(13) 	31 697
Liabilities
Deferred income tax liabilities 	8 697 	(6) 	8 691
Financial liabilities
– Borrowings at amortised cost 	14 682 	749 	15 431
– Other payables at amortised cost 	10 262 	(63) 	10 199
Total impact on equity and liabilities 	667
The increase in Property and equipment and Borrowings at amortised cost related to:
R million
Property and
equipment
Borrowings at
amortised cost
Land and buildings 	602 	682
Computer equipment and operating systems 	64 	66
Motor vehicles 	1 	1
667 	749
Restatement due to incorrect prior period classification
The reclassifications had no effect on the reported ‘Net Income’, ‘Profit for the period’ or associated earnings per share values. The restatements
do not affect any financial information published in the Annual Financial Statements for the year ended 30 June 2019.
The restatements are as a result of reclassification of amounts between separate line items within the ‘Net income’ subtotal in the Income
Statement to align the amounts presented to the stated accounting policies of the Group arising from the adoption of IFRS 15 Revenue from
Contracts with Customers and IFRS 9 Financial Instruments.
‘Fee income from administration businesses’ includes fee income earned from health administration, managed care services, asset administration
and fees earned on use of intellectual property. ‘Vitality income’ includes fee income that members or corporates pay to access the Vitality
benefit. Other fees earned are included in ‘Other income’. In the period for the six months ended 31 December 2018, R201 million of other fees
earned was incorrectly presented as part of fee income from administration businesses. The amounts were restated by reducing ‘Fee income
from administration businesses’ by R201 million and increasing ‘Other income’ with R201 million. In addition, R464 million of fees earned on use
of intellectual property was incorrectly presented as part of Vitality income. The amounts were restated by reducing ‘Vitality income’ by
R464 million and increasing ‘Fee income from administration businesses’ by R464 million.
‘Investment income’ reflects the interest earned on instruments measured at amortised cost. Interest earned on instruments measured at fair
value through profit or loss is included in the line item ‘Net fair value gains/(losses) on financial assets at fair value through profit or loss’. In the
period for the six months ended 31 December 2018, R319 million of interest earned on instruments at fair value through profit or loss was
incorrectly presented in ‘Investment income’. The amounts were restated by reducing ‘Investment income’ by R319 million and increasing ‘Net
fair value gains/(losses) on financial assets at fair value through profit or loss’ by R319 million.
27

-- 29 of 42 --

The embedded value of Discovery consists of the following components:
the adjusted net worth attributed to the business at the valuation date;
plus: the present value of expected future shareholder cash flows from the in-force covered business;
less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax
shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose
distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new business
written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and cost of required capital.
The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Limited group. Covered
business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and
Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health, MyOwn Health,
Discovery Insure and VitaltyInvest, no published value has been placed on the current in-force business as the businesses have not yet reached
suitable scale with predictable experience.
In August 2011, Discovery raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference shares.
For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
The 31 December 2019 embedded value results and disclosures were not subjected to an external review or audit.
EMBEDDED VALUE STATEMENT
for the six months ended 31 December 2019
28	Unaudited interim results and cash dividend declaration December 2019

-- 30 of 42 --

Table 1: Group embedded value
R million
31 December
2019
31 December
2018
%
change
30 June
2019
Shareholders’ funds 	44 681 	39 954 	12 	43 083
Adjustment to shareholders’ funds from published basis1 	(34 977) 	(30 858) 	(32 690)
Adjusted net worth2 	9 704 	9 096 	10 393
Value of in-force covered business before cost of required capital 	66 707 	61 668 	63 862
Cost of required capital 	(3 227) 	(2 739) 	(3 038)
Discovery Limited embedded value 	73 184 	68 025 	8 	71 217
Number of shares (millions) 	656.7 	656.6 	656.6
Embedded value per share 	R111.44 	R103.60 	8 	R108.46
Diluted number of shares (millions) 	657.6 	657.6 	657.6
Diluted embedded value per share3 	R111.29 	R103.44 	8 	R108.30
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the closing exchange rate of
R18.50/GBP (June 2019: R17.98/GBP; December 2018: R18.33/GBP):
R million
31 December
2019
31 December
2018
30 June
2019
Life net assets under insurance contracts 	(22 355) 	(19 413) 	(20 764)
Vitality Life Limited and Discovery funded VitalityLife business on the Prudential licence net assets under
insurance contracts 	(6 231) 	(5 413) 	(5 812)
VitalityHealth financial reinsurance asset 	(2 600) 	(2 127) 	(2 315)
VitalityHealth and VitalityHealth Insurance Limited deferred acquisition costs (net of deferred tax) 	(365) 	(371) 	(382)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(19) 	(27) 	(19)
Goodwill relating to the acquisition of Standard Life Healthcare and the Prudential joint venture 	(2 289) 	(2 268) 	(2 225)
Intangible assets (net of deferred tax) in covered businesses 	(964) 	(811) 	(800)
Net preference share capital 	(779) 	(779) 	(779)
Reversal of 1 Discovery Place IAS 17 financial lease accounting 	625 	351 	406
(34 977) 	(30 858) 	(32 690)
2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value:
R million
31 December
2019
31 December
2018
30 June
2019
Shareholders’ funds 	44 681 	39 954 	43 083
Adjustment to shareholders' funds 	(34 977) 	(30 858) 	(32 690)
Adjusted net worth 	9 704 	9 096 	10 393
Excess of available capital over adjusted net worth 	25 668 	25 291 	26 773
Available capital 	35 372 	34 387 	37 166
Required capital 	29 416 	27 944 	30 987
Excess available capital 	5 956 	6 443 	6 179
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes:
The net preference share capital of R779 million which is included as available capital.
The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth and adds back the negative reserves eliminated on the Discovery funded
VitalityLife business on the Prudential licence.
The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The required capital at December 2019 for Life is R20 348 million (June 2019: R21 724 million; December 2018: R19 673 million), for Health and Vitality is R949 million
(June 2019: R909 million; December 2018: R886 million), for VitalityHealth is R2 411 million (June 2019: R2 350 million; December 2018: R2 240 million) and for VitalityLife is
R5 708 million (June 2019: R6 004 million; December 2018: R5 145 million). For Life, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. For VitalityHealth, the required capital amount was
set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement. For the VitalityLife business on the Prudential licence, the required capital was set equal to the UK
Solvency I long term insurance capital requirement as per the agreement with Prudential. For the business sold on the Vitality Life Limited licence, the required capital was set
equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement.
3 The diluted embedded value per share allows for Discovery’s BEE transaction where the impact is dilutive i.e. where the current embedded value per share exceeds the current
transaction value.
29

-- 31 of 42 --

EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2019
Table 2: Value of in-force covered business
R million
Value before
cost of
required
capital
Cost of
required
capital
Value after
cost of
required
capital
at 31 December 2019
Health and Vitality 	21 574 	(404) 	21 170
Life and Invest1 	28 812 	(1 230) 	27 582
VitalityHealth2 	8 399 	(388) 	8 011
VitalityLife2 	7 922 	(1 205) 	6 717
Total 	66 707 	(3 227) 	63 480
at 31 December 2018
Health and Vitality 	21 274 	(391) 	20 883
Life and Invest1 	25 834 	(1 091) 	24 743
VitalityHealth2 	7 443 	(353) 	7 090
VitalityLife2 	7 117 	(904) 	6 213
Total 	61 668 	(2 739) 	58 929
at 30 June 2019
Health and Vitality 	21 465 	(394) 	21 071
Life and Invest1 	27 277 	(1 177) 	26 100
VitalityHealth 2 	7 840 	(378) 	7 462
VitalityLife2 	7 280 	(1 089) 	6 191
Total 	63 862 	(3 038) 	60 824
1 Included in the Life and Invest value of in-force covered business is R1 522 million (June 2019: R1 429 million; December 2018: R1 303 million) in respect of investment management
services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R18.50/GBP (June 2019: R17.98/GBP; December 2018: R18.33/GBP).
Table 3: Group embedded value earnings
Six months ended 	Year ended
R million
31 December
2019
31 December
2018
30 June
2019
Embedded value at end of period 	73 184 	68 025 	71 217
Less: Embedded value at beginning of period 	(71 217) 	(65 624) 	(65 624)
Increase in embedded value 	1 967 	2 401 	5 593
Net change in capital1 	– 	(1 840) 	(1 839)
Dividends paid 	789 	776 	1 481
Transfer to hedging reserve 	102 	27 	175
Employee share option schemes 	(58) 	(7) 	(33)
Increase in treasury shares 	– 	– 	5
Acquisition of subsidiaries with non-controlling interest2 	(6) 	– 	–
Change in ownership3 	– 	1 104 	1 104
IFRS transitional arrangements4 	13 	77 	73
Embedded value earnings 	2 807 	2 538 	6 559
Annualised return on opening embedded value 	8.0% 	7.9% 	10.0%
1 The net change in capital reflects share issues (net of costs) and an increase (decrease) in treasury shares in the period.
2 This balance arose from the acquisition of the MSO Group in Health.
3 The change in ownership reflects the acquisition of the remaining 48.87% interest in Discovery Bank from FRIHL, being the non-controlling interest.
4 The IFRS transitional arrangements reflects the retrospective adjustments arising from the adoption of IFRS 9 and IFRS 15 to the opening balances at 1 July 2018.
30	Unaudited interim results and cash dividend declaration December 2019

-- 32 of 42 --

Table 4: Components of Group embedded value earnings
Six months ended 31 December 2019
Six months
ended
31 December
2018
Year ended
30 June 2019
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Embedded
value
Embedded
value
Embedded
value
Total profit from new business (at point of sale) 	(2 496) 	(174) 	3 866 	1 196 	1 300 	2 622
Profit from existing business
Expected return 	3 037 	– 	(428) 	2 609 	2 858 	6 000
Change in methodology and assumptions1 	759 	71 	(1 595) 	(765) 	(332) 	(1 930)
Experience variances 	33 	(44) 	553 	542 	(656) 	19
Impairment, amortisation and fair value
adjustment2 	(8) 	– 	– 	(8) 	(31) 	(37)
Increase in goodwill and intangibles 	(271) 	– 	– 	(271) 	(113) 	(244)
Other initiative costs3 	(546) 	– 	20 	(526) 	(288) 	914
Non-recurring expenses 	– 	– 	– 	– 	(102) 	(3)
Acquisition costs4 	(6) 	– 	(4) 	(10) 	(22) 	(39)
Finance costs 	(553) 	– 	– 	(553) 	(494) 	(1 060)
Foreign exchange rate movements 	3 	(42) 	432 	393 	189 	(178)
Other5 	– 	– 	1 	1 	58 	76
Return on shareholders’ funds6 	199 	– 	– 	199 	171 	419
Embedded value earnings 	151 	(189) 	2 845 	2 807 	2 538 	6 559
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and economic
environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, the PrimeMed acquisition and capital expenditure in VitalityInvest.
3 This item includes profits and costs of start-up businesses, and expenses incurred to investigate new products and markets. Start-up costs include costs in relation to the Discovery
Bank, VitalityInvest, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest. Head office costs which relate to non-covered business are also included
in this item. Included in this item for 30 June 2019 are once-off gains from the dilution of Discovery Insure’s investment in Cambridge Mobile Telematics.
4 Acquisition costs relate to commission paid on the Life business and expenses incurred in writing Health and Vitality business that has been written over the period but will only be
activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the costs are not deducted from
the value of new business.
5 This item includes, among other items, the tax benefits or losses that will emerge as the VitalityHealth DAC and intangible software assets amortise or increase.
6 The return on shareholders’ funds is shown net of tax and management charges.
31

-- 33 of 42 --

EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2019
Table 5: Experience variances
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	56 	– 	9 	– 	26 	– 	15 	– 	106
Lapses and surrenders1 	(1) 	(132) 	61 	1 	– 	238 	(23) 	(47) 	97
Mortality and morbidity 	– 	– 	(48) 	(29) 	(56) 	– 	(21) 	– 	(154)
Policy alterations 2 	– 	(12) 	(290) 	306 	– 	– 	(8) 	(21) 	(25)
Premium and fee income3 	68 	– 	– 	89 	24 	– 	(5) 	(15) 	161
Economic4 	4 	145 	(10) 	(184) 	– 	– 	– 	– 	(45)
Commission 	– 	– 	– 	– 	20 	– 	– 	– 	20
Tax5 	72 	– 	137 	(101) 	110 	– 	34 	– 	252
Reinsurance 	– 	– 	– 	– 	(35) 	– 	34 	(49) 	(50)
Maintain modelling term6 	– 	159 	– 	88 	– 	30 	– 	– 	277
Vitality benefits 	(11) 	– 	– 	– 	– 	– 	(3) 	– 	(14)
Other7 	22 	1 	(61) 	62 	52 	– 	(139) 	(20) 	(83)
Total 	210 	161 	(202) 	232 	141 	268 	(116) 	(152) 	542
1 The lapse and surrender experience for Health and Vitality relates to lower than expected additions to existing compulsory scheme membership.
2 The policy alterations experience for Life and Invest arises largely due to servicing and fund switches.
3 The premium and fee income experience for Life arises largely due to the impact of Vitality status distribution shifts compared to expected levels.
4 The economic experience for Health and Vitality relates to the impact on administration and managed care fees due to the in-period inflation being higher than that assumed.
5 The tax variance for Life and Invest arises due to a movement in the deferred tax asset which delays the payment of tax.
6 The projection term for Health and Vitality, Life and VitalityHealth at 31 December 2019 has not been changed from that used in the 30 June 2019 embedded value calculation.
Therefore, an experience variance arises because the total term of the in-force covered business is effectively increased by six months.
7 The other experience for VitalityLife includes, amongst other things, the cost of the interest rate hedge.
Table 6: Methodology and assumption changes
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes1 	– 	– 	(1) 	130 	– 	– 	(6) 	57 	180
Expenses 	– 	– 	– 	9 	– 	– 	– 	– 	9
Lapses 	– 	– 	– 	– 	– 	– 	– 	– 	–
Mortality and morbidity 	– 	– 	– 	– 	– 	– 	– 	– 	–
Benefit changes 	– 	(1) 	(4) 	10 	– 	– 	– 	– 	5
Tax 	– 	– 	– 	– 	– 	– 	– 	54 	54
Economic assumptions2 	– 	(203) 	13 	(671) 	– 	– 	(10) 	(76) 	(947)
Premium and fee income 	– 	– 	– 	– 	– 	– 	– 	– 	–
Reinsurance3 	– 	– 	782 	(784) 	– 	(15) 	– 	– 	(17)
Other4 	– 	– 	– 	(15) 	– 	– 	(15) 	(19) 	(49)
Total 	– 	(204) 	790 	(1 321) 	– 	(15) 	(31) 	16 	(765)
1 For Life, the modelling changes line predominately relates to corrections on policy data. For VitalityLife, this line includes a product update, refinements to the required capital
calculations and an allowance for the loss absorbing capacity of deferred taxes in the required capital.
2 For Life, Invest, Health and Vitality the economic assumptions item relates to the impact of updating the assumptions relative to the publically available Prudential Authority
nominal and real yield risk-free curves at 31 December 2019. For VitalityLife the item relates to the impact of the Solvency II swap curve on the cost capital.
3 For Life, the reinsurance item primarily relates to the impact of the financing reinsurance arrangements.
4 For VitalityLife, the other item relates to the margin reset to offset experience variances, as per the accounting policy.
32	Unaudited interim results and cash dividend declaration December 2019

-- 34 of 42 --

Table 7: Embedded value of new business
Six months ended 	Year ended
R million
31 December
2019
31 December
2018
%
change
30 June
2019
Health and Vitality
Present value of future profits from new business (at point of sale) 	391 	428 	832
Cost of required capital 	(14) 	(14) 	(27)
Present value of future profits from new business (at point of sale)
after cost of required capital 	377 	414 	(9) 	805
New business annualised premium income1 	1 714 	1 668 	3 	3 716
Life and Invest
Present value of future profits from new business (at point of sale)2 	570 	668 	1 242
Cost of required capital 	(44) 	(41) 	(82)
Present value of future profits from new business (at point of sale)
after cost of required capital 	526 	627 	(16) 	1 160
New business annualised premium income3 	1 457 	1 546 	(6) 	2 897
Annualised profit margin4 	4.3% 	4.8% 	4.6%
Annualised profit margin excluding Invest business 	9.5% 	10.7% 	10.2%
VitalityHealth 5
Present value of future profits from new business (at point of sale) 	121 	119 	330
Cost of required capital 	(26) 	(26) 	(59)
Present value of future profits from new business (at point of sale)
after cost of required capital 	95 	93 	2 	271
New business annualised premium income (Rand)6 	609 	606 	0 	1 294
Annualised profit margin4 	2.5% 	2.5% 	3.2%
VitalityLife 7
Present value of future profits from new business (at point of sale) 	288 	230 	520
Cost of required capital 	(90) 	(64) 	(134)
Present value of future profits from new business (at point of sale)
after cost of required capital 	198 	166 	19 	386
New business annualised premium income (Rand) 	524 	503 	4 	995
Annualised profit margin4 	4.9% 	4.3% 	5.0%
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown above excludes
premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new business written
during the period but only activated after 31 December 2019.
The total Health and Vitality new business annualised premium income written over the period was R3 360 million (June 2019: R6 801 million; December 2018: R3 517 million).
2 Included in the Life and Invest embedded value of new business is R22 million (June 2019: R70 million; December 2018: R43 million) in respect of investment management services
provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been recognised in the
value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after the valuation
date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new business also includes
Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies whose first premium is due after the
valuation date.
The new business annualised premium income of R1 457 million (June 2019: R2 897 million; December 2018: R1 546 million) (single premium APE: R635 million (June 2019:
R1 321 million; December 2018: R699 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business
annualised premium income written over the period, including automatic premium increases of R773 million (June 2019: R1 370 million; December 2018: R704 million) and
servicing increases of R367 million (June 2019: R648 million; December 2018: R349 million), was R2 597 million (June 2019: R4 915 million; December 2018: R2 599 million) (single
premium APE: R671 million (June 2019: R1 382 million; December 2018: R725 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances and not
included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the Margin
multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium income shown
above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect of new business
written during the period but only activated after 31 December 2019.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due after the
valuation date.
33

-- 35 of 42 --

EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2019
BASIS OF PREPARATION
Table 8: Embedded value economic assumptions
31 December
2019
31 December
2018
30 June
2019
Beta coefficient 	0.75 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5 	3.5
Risk discount rate (%)
Health and Vitality1 	12.375 	12.375 	11.875
Life and Invest1 	13.435 	13.125 	13.125
VitalityHealth 	3.61 	4.02 	3.61
VitalityLife 	4.725 	4.725 	4.725
Rand/GB Pound exchange rate
Closing 	18.50 	18.33 	17.98
Average 	18.53 	18.27 	18.32
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00 	3.00
Expense inflation (%)
South Africa2 	– Health and Vitality 	6.29 	6.84 	6.13
– Life and Invest 	7.28 	7.49 	7.24
United Kingdom 	3.00 	3.00 	3.00
Pre-tax investment return (%)
South Africa 	– Cash1 	9.31 	9.00 	9.00
– Life and Invest bonds3 	10.81 	10.50 	10.50
– Health and Vitality bonds3 	9.75 	9.75 	9.25
– Equity1 	14.00 	14.00 	14.00
United Kingdom – VitalityHealth investment return 	0.99 	1.40 	0.99
– VitalityLife investment return 	2.10 	2.50 	2.10
Income tax rate (%)
South Africa 	28 	28 	28
United Kingdom – long term4 	17 	17 	17
VitalityHealth Assumptions
– Margin (net of tax and cost of capital) (%) 	14.1 	14.1 	14.1
– Annuity Factor 	6.13 	6.00 	6.13
Projection term
– Health and Vitality 	20 years 	20 years 	20 years
– Discovery Life – ViF 	40 years 	40 years 	40 years
– Group Life 	10 years 	10 years 	10 years
– VitalityLife 	No cap 	No cap 	No cap
– VitalityHealth5 	20 years 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation is shown
in the table.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The United Kingdom Corporation tax rate assumed is 19% in 2019 to 2020, and 17% beyond that.
5 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.
34	Unaudited interim results and cash dividend declaration December 2019

-- 36 of 42 --

The Discovery Limited embedded value is calculated based on a risk discount rate using the CAPM approach with specific reference to the
Discovery beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the result of a Weighted
Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta calculated using daily returns over
a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta will only change if the capital structure of the
Group and / or the observed beta calculated using daily returns over a long time period suggest the beta assumption should depart significantly
from the assumption at the financial year end. As beta values reflect the historic performance of share prices relative to the market they may
not allow fully for non-market related and non-financial risk. Investors may want to form their own view on an appropriate allowance for these
risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available, augmented
by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Limited
group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of an
exceptional or non-recurring nature.
From 30 June 2018, the South African investment return assumptions for Life, Invest, Health and Vitality were based on the publically available
Prudential Authority risk-free nominal yield curve. The real yield assumption was set based on the publically available Prudential Authority risk-
free real yield curve, adjusted to remove volatility due to the nature of the index linked government bond market. Other economic assumptions
were set relative to these two yield curves.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the net
investment return assumption.
The best estimate investment return assumption for VitalityHealth was based on the single interest rate derived from the risk-free zero coupon
sterling yield curve.
From 30 June 2018, VitalityHealth calculate the value in-force at the valuation date as the in-force written premium multiplied by the Margin
multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse rates and
premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The assumptions underlying the Annuity Factor
and Margin are set taking into account the current experience in the business at different durations.
VitalityLife adopts a passive approach for setting economic assumptions. The nominal investment return and real return rate are fixed unless
market conditions depart significantly from the assumptions at the financial year end. Other economic assumptions were set relative to these
two passive yields.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible assets.
Vitality Life Limited and the VitalityLife business on the Prudential licence required capital amount is assumed to earn the same return as the
assets backing the VitalityLife policyholder liabilities. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is
limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital requirement
of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into account
the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.
35

-- 37 of 42 --

EMBEDDED VALUE STATEMENT continued
for the six months ended 31 December 2019
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery beta coefficient. As beta values reflect the historic
performance of share prices relative to the market they may not allow fully for non-market related and non-financial risk. Investors may want
to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded
value and the embedded value of new business at 31 December 2019 to changes in the risk discount rate is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action
such as risk premium increases where future experience is worse than the base assumptions.
Table 9: Embedded value sensitivity
Health and Vitality
R million
Adjusted
net worth2
Value
of
in-force
Cost of
required
capital
Base 	9 704 	21 574 	(404)
Impact of:
Risk discount rate +1% 	9 704 	20 320 	(439)
Risk discount rate -1% 	9 704 	22 966 	(364)
Lapses -10% 	9 520 	22 301 	(424)
Interest rates -1%1 	8 832 	21 700 	(388)
Equity and property market value -10% 	9 667 	21 574 	(404)
Equity and property return +1% 	9 704 	21 574 	(404)
Renewal expenses -10% 	9 778 	23 695 	(374)
Mortality and morbidity -5% 	9 888 	21 574 	(404)
Projection term +1 year 	9 704 	21 884 	(409)
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
Table 10: Value of new business sensitivity
Health and Vitality
R million
Value of
new
business
Cost of
required
capital
Base 	391 	(14)
Impact of:
Risk discount rate +1% 	357 	(15)
Risk discount rate -1% 	429 	(12)
Lapses -10% 	414 	(14)
Interest rates -1%1 	397 	(13)
Equity and property return +1% 	391 	(14)
Renewal expense -10% 	449 	(13)
Mortality and morbidity -5% 	391 	(14)
Projection term +1 year 	400 	(14)
Acquisition costs -10% 	404 	(14)
1 All economic assumptions were reduced by 1%.
36	Unaudited interim results and cash dividend declaration December 2019

-- 38 of 42 --

Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
28 812 	(1 230) 	8 399 	(388) 	7 922 	(1 205) 	73 184
26 102 	(1 142) 	7 968 	(368) 	7 435 	(1 443) 	68 137 	(7)
32 016 	(1 333) 	8 874 	(410) 	8 496 	(872) 	79 077 	8
31 161 	(1 320) 	9 468 	(437) 	8 495 	(1 403) 	77 361 	6
29 515 	(1 319) 	8 733 	(410) 	7 904 	(1 808) 	72 759 	(1)
28 358 	(1 264) 	8 398 	(388) 	7 922 	(1 205) 	72 658 	(1)
29 148 	(1 233) 	8 450 	(388) 	7 922 	(1 205) 	73 568 	1
29 270 	(1 185) 	9 023 	(388) 	8 036 	(1 150) 	76 705 	5
30 678 	(1 043) 	9 690 	(388) 	8 106 	(1 167) 	76 934 	5
28 970 	(1 242) 	8 456 	(391) 	7 922 	(1 205) 	73 689 	1
Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
570 	(44) 	121 	(26) 	288 	(90) 	1 196
429 	(41) 	89 	(24) 	222 	(105) 	912 	(24)
737 	(48) 	157 	(27) 	364 	(68) 	1 532 	28
720 	(48) 	188 	(29) 	370 	(112) 	1 489 	24
598 	(48) 	148 	(27) 	301 	(141) 	1 215 	2
585 	(45) 	125 	(26) 	288 	(90) 	1 214 	2
592 	(43) 	161 	(26) 	302 	(81) 	1 341 	12
629 	(38) 	203 	(26) 	311 	(82) 	1 374 	15
578 	(45) 	125 	(26) 	288 	(90) 	1 216 	2
647 	(44) 	139 	(26) 	348 	(81) 	1 373 	15
37

-- 39 of 42 --

38	Unaudited interim results and cash dividend declaration December 2019

-- 40 of 42 --

Transfer secretaries Computershare Investor Services Pty Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank 2196
PO Box 61051, Marshalltown 2107
Sponsors Rand Merchant Bank (A division of FirstRand Bank Limited)
Secretary and registered office MJ Botha, Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: DSY ISIN: ZAE000022331
JSE share code: DSBP ISIN: ZAE000158564
JSE bond code: DSYI
1 Discovery Place, Sandton 2146 PO Box 786722, Sandton 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Chief Executive Officer), HL Bosman, Dr BA Brink, SE de Bruyn, R Farber, HD Kallner*,
F Khanyile, NS Koopowitz*, D Macready1, Dr TV Maphai, HP Mayers2, Dr A Ntsaluba*, AL Owen (UK)3
, A Pollard*, B Swartzberg*,
DM Viljoen* (Financial Director), SV Zilwa
* Executive.
1 Appointed effective 3 February 2020.
2 Redesignated as a non-executive director effective 28 November 2019.
3 Retired effective 14 February 2020.
Interim financial results
– prepared by L van Jaarsveldt CA(SA) and A Nel CA(SA)
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by M Curtis FASSA, FIA and P Bolink FASSA
– supervised by A Rayner FASSA, FIA

-- 41 of 42 --

Discovery
Contact +27 11 529 2888 | Investor_Relations@discovery.co.za | www.discovery.co.za
Discovery is an authorised financial services provider.

-- 42 of 42 --